

This Page Is Inserted by IFW Operations  
and is not a part of the Official Record

## **BEST AVAILABLE IMAGES**


Defective images within this document are accurate representations of  
The original documents submitted by the applicant.

Defects in the images may include (but are not limited to):

- BLACK BORDERS
- TEXT CUT OFF AT TOP, BOTTOM OR SIDES
- FADED TEXT
- ILLEGIBLE TEXT
- SKEWED/SLANTED IMAGES
- COLORED PHOTOS
- BLACK OR VERY BLACK AND WHITE DARK PHOTOS
- GRAY SCALE DOCUMENTS

**IMAGES ARE BEST AVAILABLE COPY.**

**As rescanning documents *will not* correct images,  
please do not report the images to the  
Image Problem Mailbox.**

|  |                |   |                    |
|--|----------------|---|--------------------|
| EAR CODE LABEL<br>  |                | PCT/US92/02190<br>U.S. PATENT APPLICATION<br>92910625 |                    |
| SERIAL NUMBER  | FILING DATE    | CLASS   | GROUP ART UNIT     |
| 07/670,827   | 03/18/91       | 424   | 186                |
| APPLICANT<br>JUNMING LE, JACKSON HGTS., NY; JAN VILCEK, NEW YORK, NY; PETER E. DADDONA, WEST CHESTER, PA; JOHN GHAYEB, THORNDALE, PA; DAVID M. KNIGHT, PAOLI, PA; SCOTT A. SIEGEL, WEST CHESTER, PA. |                |   |                    |
| **CONTINUING DATA*****<br>VERIFIED   |                | RE 10 JUN 1992<br>WIPO PCT                            |                    |
| **FOREIGN/PCT APPLICATIONS*****<br>VERIFIED  |                | PRIORITY DOCUMENT                                     |                    |
| FOREIGN FILING LICENSE GRANTED 06/28/91  |                |   |                    |
| STATE OR COUNTRY   | SHEETS DRAWING | TOTAL CLAIMS  | INDEPENDENT CLAIMS |
| NY   | 12             | 42  | 5                  |
| FILING FEE RECEIVED  |                | ATTORNEY DOCKET NO.                                   |                    |
| \$1,310.00   |                | LE-1  |                    |
| BROWDY & NEIMARK<br>119 7TH ST, NW<br>WASHINGTON, DC 20004   |                |   |                    |
| MONOCLONAL AND CHIMERIC ANTIBODIES SPECIFIC FOR HUMAN TUMOR<br>NECROSIS FACTOR   |                |   |                    |
| This is to certify that annexed hereto is a true copy from the records of the United States Patent and Trademark Office of the application as originally filed which is identified above.            |                |   |                    |
| By authority of the<br>COMMISSIONER OF PATENTS AND TRADEMARKS  |                | Certifying Officer <i>J. E. Smith</i>                 |                    |
| Date APR 03 1992   |                |   |                    |

AP4

11 18 00 00

PATENT APPLICATION SERIAL NO. 670827

U.S. DEPARTMENT OF COMMERCE  
PATENT AND TRADEMARK OFFICE  
FEE RECORD SHEET

LA1012L 03/21/91 07670827 02-+035 010 101 630.00CH LE-1

PTO-1556  
(5/87)



670825

MONOCLONAL AND CHIMERIC ANTIBODIES SPECIFIC FOR  
HUMAN TUMOR NECROSIS FACTOR

BACKGROUND OF THE INVENTION

FIELD OF THE INVENTION

5 The invention in the field of immunology and medicine relates to monoclonal and chimeric antibodies specific for human tumor necrosis factor-alpha (hTNF $\alpha$ ), their fragments and derivatives, pharmaceutical compositions containing them, methods of producing them, uses for the antibodies in diagnosis and  
10 therapy of human disease. The invention further relates to nucleotide sequences encoding the chimeric antibodies, and vectors and hosts containing the sequences.

DESCRIPTION OF THE BACKGROUND ART

General Properties of TNF and Its Role in Disease

15 The cytokine known as tumor necrosis factor- $\alpha$  (TNF; also termed cachectin) is a protein secreted primarily by monocytes and macrophages in response to endotoxin or other stimuli as a soluble homotrimer of 17 kD protein subunits (Smith, R.A. et al., J. Biol. Chem. 262:6951-6954 (1987)). A membrane-  
20 bound 26 kD precursor form of TNF has also been described (Kriegler, M. et al., Cell 53:45-53 (1988)). For reviews of TNF, see Beutler, B. et al., Nature 320:584 (1986), Old, L.J., Science 230:630 (1986), and Le, J. et al., Lab. Invest. 56:234 (1987). TNF was originally discovered in the serum of animals injected



sequentially with a bacterial vaccine (bacillus Calmette-Guerin, BCG) and endotoxin (Carswell, E.A. et al., Proc. Natl. Acad. Sci. USA 72:3666 (1975)).

5 The expression of the gene encoding TNF is not limited to cells of the monocyte/macrophage family. Several human non-monocytic tumor cell lines were shown to produce TNF (Rubin, B.Y. et al., J. Exp. Med. 164:1350 (1986); Spriggs, D. et al., Proc. Natl. Acad. Sci. USA 84:6563 (1987)). TNF is also produced by CD4<sup>+</sup> and CD8<sup>+</sup> peripheral blood T lymphocytes, and by various  
10 cultured T and B cell lines (Cuturi, M.C., et al., J. Exp. Med. 165:1581 (1987); Sung, S.-S.J. et al., J. Exp. Med. 168:1539 (1988)).

Accumulating evidence indicates that TNF is a regulatory cytokine with pleiotropic biological activities.  
15 These activities include: inhibition of lipoprotein lipase synthesis ("cachectin" activity) (Beutler, B. et al., Nature 316:552 (1985)), activation of polymorphonuclear leukocytes (Klebanoff, S.J. et al., J. Immunol. 136:4220 (1986); Perussia, B., et al., J. Immunol. 138:765 (1987)), inhibition of cell  
20 growth or stimulation of cell growth (Vilcek, J. et al., J. Exp. Med. 161:632 (1986); Sugarman, B.J. et al., Science 230:943 (1985); Lachman, L.B. et al., J. Immunol. 138:2913 (1987)), cytotoxic action on certain transformed cell types (Lachman, L.B. et al., supra; Darzynkiewicz, Z. et al., Canc. Res. 44:83  
25 (1984)), antiviral activity (Kohase, M. et al., Cell 45:659 (1986); Wong, G.H.W. et al., Nature 323:819 (1986)), stimulation

14 10 02 02

of bone resorption (Bertolini, D.R. et al., Nature 319:516 (1986); Saklatvala, J., Nature 322:547 (1986)), stimulation of collagenase and prostaglandin E2 production (Dayer, J.-M. et al., J. Exp. Med. 162:2163 (1985)); and immunoregulatory actions, including activation of T cells (Yokota, S. et al., J. Immunol. 140:531 (1988)), B cells (Kehrl, J.H. et al., J. Exp. Med. 166:786 (1987)), monocytes (Philip, R. et al., Nature 323:86 (1986)), thymocytes (Ranges, G.E. et al., J. Exp. Med. 167:1472 (1988)), and stimulation of the cell-surface expression of major histocompatibility complex (MHC) class I and class II molecules (Collins, T. et al., Proc. Natl. Acad. Sci. USA 83:446 (1986); Fujol-Borrell, R. et al., Nature 326:304 (1987)).

TNF is noted for its pro-inflammatory actions which result in tissue injury, such as induction of procoagulant activity on vascular endothelial cells (Pober, J.S. et al., J. Immunol. 136:1680 (1986)), increased adherence of neutrophils and lymphocytes (Pober, J.S. et al., J. Immunol. 138:3319 (1987)), and stimulation of the release of platelet activating factor from macrophages, neutrophils and vascular endothelial cells (Camussi, G. et al., J. Exp. Med. 166:1390 (1987)).

Recent evidence implicates TNF in the pathogenesis of many infections (Cerami, A. et al., Immunol. Today 9:28 (1988)), immune disorders, neoplastic disease, e.g., in cachexia accompanying some malignancies (Oliff, A. et al., Cell 50:555 (1987)), and in autoimmune diseases and graft-versus host disease (Piquet, P.-F. et al., J. Exp. Med. 166:1280 (1987)). The

association of TNF with cancer and infectious diseases is often related to the host's catabolic state. A major problem in cancer patients is weight loss, usually associated with anorexia. The extensive wasting which results is known as "cachexia"

5 (Kern, K.A. et al. (J. Parent. Enter. Nutr. 12:286-298 (1988))). Cachexia includes progressive weight loss, anorexia, and persistent erosion of body mass in response to a malignant growth. The fundamental physiological derangement may be related to a decline in food intake relative to energy expenditure. The  
10 cachectic state is thus associated with significant morbidity and is responsible for the majority of cancer mortality. A number of studies have suggested that TNF is an important mediator of the cachexia in cancer, infectious disease, and in other catabolic states.

15 TNF is thought to play a central role in the pathophysiological consequences of Gram-negative sepsis and endotoxic shock (Michie, H.R. et al., Br. J. Surg. 76:670-671 (1989); Debets, J.M.H. et al., Second Vienna Shock Forum, p.463-466 (1989); Simpson, S.Q. et al., Crit. Care Clin. 5:27-  
20 47 (1989)), including fever, malaise, anorexia, and cachexia. Endotoxin is a potent monocyte/macrophage activator which stimulates production and secretion of TNF (Kornbluth, S.K. et al., J. Immunol. 137:2585-2591 (1986)) and other cytokines. Because TNF could mimic many biological effects of endotoxin, it  
25 was concluded to be a central mediator responsible for the clinical manifestations of endotoxin-related illness. TNF and

other monocyte-derived cytokines mediate the metabolic and neurohormonal responses to endotoxin (Michie, H.R. et al., N. Eng. J. Med. 118:1481-1486 (1988)). Endotoxin administration to human volunteers produces acute illness with flu-like symptoms including fever, tachycardia, increased metabolic rate and stress hormone release (Revhaug, A. et al., Arch. Surg. 121:162-170 (1988)). Elevated levels of circulating TNF have also been found in patients suffering from Gram-negative sepsis (Waage, A. et al., Lancet 1:355-357 (1987); Hammerle, A.F. et al., Second Vienna Shock Forum p. 715-718 (1989); Debets, J.M.H. et al., Crit. Care Med. 17:489-497 (1989); Calandra, T. et al., J. Infect. Dis. 161:982-987 (1990)). Treatment of cancer patients with TNF (because of its tumoricidal action) revealed that doses greater than 545  $\mu\text{g}/\text{m}^2/24\text{hr}$  caused alterations similar to those induced by injection of endotoxin (4 ng/kg) into healthy humans (Michie, H.R. et al., Surgery 104:280-286 (1988)), supporting TNF's role as the principal host mediator of septic and endotoxemic responses. Chronic intravenous TNF infusion into humans or rats was associated with anorexia, fluid retention, acute phase responses, and negative nitrogen balance (i.e., classic catabolic effects), leading to the conclusion that TNF may be responsible for many of the changes noted during critical illness (Michie, H.R. et al., Ann. Surg. 209:19-24 (1989)).

Antibodies to TNF and Their Use in Diagnosis and Therapy

Passive immunotherapy directed at neutralizing TNF may have a beneficial effect in Gram-negative sepsis and endotoxemia, based on the increased TNF production and elevated TNF levels in these disease states, as discussed above.

- 5           Antibodies to a "modulator" material which was characterized as cachectin (later found to be identical to TNF) were disclosed by Cerami et al. (EPO Patent Publication 0212489, March 4, 1987). Such antibodies were said to be useful in diagnostic immunoassays and in therapy of shock in bacterial
- 10   infections. Rubin et al. (EPO Patent Publication 0218868, April 22, 1987) disclosed monoclonal antibodies to human TNF, the hybridomas secreting such antibodies, methods of producing such antibodies, and the use of such antibodies in immunoassay of TNF. Yone et al. (EPO Patent Publication 0288088, October 26, 1988)
- 15   disclosed anti-TNF antibodies, including mAbs, and their utility in immunoassay diagnosis of diseases, in particular Kawasaki's disease and bacterial infection. The body fluids of patients with Kawasaki's disease (infantile acute febrile mucocutaneous lymph node syndrome; Kawasaki, T., Allergy 16:178 (1967);
- 20   Kawasaki, T., Shonika (Pediatrics) 26:935 (1985)) were said to contain elevated TNF levels which were related to progress of the disease (Yone et al., supra).

- Other investigators have described mAbs specific for recombinant human TNF which had neutralizing activity in vitro
- 25   (Liang, C-M. et al. (Biochem. Biophys. Res. Comm. 137:847-854 (1986); Meager, A. et al., Hybridoma 6:305-311 (1987); Fendly et

al., Hybridoma 6:359-369 (1987); Bringman, T.S. et al.,  
Hybridoma 6:489-507 (1987); Hirai, M. et al., J. Immunol. Meth.  
96:57-62 (1987); Moller, A. et al. (Cytokine 2:162-169 (1990)).  
Some of these mAbs were used to map epitopes of human TNF and  
5 develop enzyme immunoassays (Fendly et al., supra; Hirai et al.,  
supra; Moller et al., supra) and to assist in the purification of  
recombinant TNF (Bringman et al., supra).

The most direct support for the use of anti-TNF  
immunotherapy comes from in vivo protection studies in animals.  
10 Neutralizing antisera or mAbs to TNF have been shown to abrogate  
adverse physiological changes and prevent death after lethal  
challenge in experimental endotoxemia and bacteremia animal model  
systems. This effect has been demonstrated in rodent lethality  
assays and in primate disease model systems (Mathison, J.C. et  
15 al., J. Clin. Invest. 81:1925-1937 (1988); Beutler, B. et al.,  
Science 229:869-871 (1985); Tracey, K.J. et al., Nature 330:662-  
664 (1987); Shimamoto, Y. et al., Immunol. Lett. 17:311-318  
(1988); Silva, A.T. et al., J. Infect. Dis. 162:421-427 (1990);  
Opal, S.M. et al., J. Infect. Dis. 161:1148-1152 (1990); Hinshaw,  
20 L.B. et al., Circ. Shock 30:279-292 (1990)). For example,  
F(ab')<sub>2</sub> fragments of neutralizing anti-TNF mAbs were able to  
prevent septic shock produced by live E. coli in baboons (Tracey,  
K.J. et al., supra).

To date, experience with anti-TNF mAb therapy in humans  
25 has been limited. In a phase I study, fourteen patients with  
severe septic shock administered a neutralizing mouse anti-TNF

14 10 0000

mAb in a single dose from 0.4-10 mg/kg (Exley, A.R. et al.,  
Lancet 315:1275-1277 (1990)), and the treatment was concluded to  
be safe and without acute side-effects. Seven of the fourteen  
patients developed a human anti-murine antibody response to the  
5 treatment. Administration of murine TNF mAb to patients  
suffering from severe graft vs. host disease has also been  
reported (Herve, P. et al., Lymphoma Res. 2:591 (1990)). While  
the results of this small study were too preliminary for  
efficacy interpretation, no acute side-effects of the treatment  
10 were noted.

#### Monoclonal and Chimeric Antibodies

Monoclonal antibody technology has spawned a revolution  
in biology equal in impact to that of recombinant DNA technology.  
MAbs produced by hybridoma cells are already widely used in  
15 diagnostics and in basic biomedical research. Their success in  
the treatment of human diseases, including microbial infections,  
autoimmune disease, and cancer, has yet to be established.  
Despite their exquisite specificity, mouse mAbs, by their very  
nature, have limitations in their applicability to human  
20 medicine. Most obviously, due to their murine origin, they are  
foreign proteins in humans, induce anti-murine immune responses  
and tend to be cleared more rapidly from the circulation. Since  
treatment of many diseases would require multiple administrations  
of a mAb, the risk of immune reactions, including anaphylaxis,  
25 may severely hamper the widespread applicability of murine mAbs

in most of the human diseases discussed above. Finally, mouse antibodies may not interact as effectively as human antibodies with human effector cells (e.g., macrophages) or with human effector molecules (e.g., complement components).

5           The development of human mAbs that could circumvent the above problems has encountered a number of obstacles. Because human spleen cell donors are rare, human mAb-producing cell lines are typically obtained from human peripheral B cells immortalized by infection with Epstein Barr Virus (EBV). Such  
10 cells may not be useful for scale-up and production of human pharmaceuticals. Furthermore, the presence of human viral genetic information in such EBV-immortalized human antibody-producing cell lines may be a barrier to their safe use. In addition, since human TNF has evolved in the face of the human  
15 immune response, key antigenic epitopes may not be recognized by the human immune system. Such antigens would not be expected to elicit useful immune responses in man. In contrast, those human antigens that are immunogenic in mice can be used for the production of mouse mAbs which may have the appropriate antigen  
20 specificity to be of therapeutic utility in humans.

A chimeric antibody may comprise an antigen binding region of non-human origin, such as that derived from a murine mAb, joined to a human constant region. Use of such chimeric antibodies has been suggested as a means for avoiding the problem  
25 of immunogenicity of murine antibodies in humans. Since the constant region is largely responsible for immunogenicity of an



antibody molecule, chimeric antibodies with human constant regions are less likely to evoke an immune response in a human. Chimeric antibodies and methods for their production have been described in the scientific and patent literature (Cabilly *et al.*,  
5 Proc. Natl. Acad. Sci. USA 81:3273-3277 (1984); Morrison *et al.*,  
Proc. Natl. Acad. Sci. USA 81:6351-6855 (1984); Boulianne  
*et al.*, Nature 312:643-646 (1984); Neuberger *et al.*, Nature  
314:268-270 (1985); Taniguchi *et al.*, European Patent Publication  
171496 (February 19, 1985); Robinson *et al.*, International Patent  
10 Publication PCT/US86/02269 (May 7, 1987); Liu *et al.*, Proc.  
Natl. Acad. Sci. USA 84:3439-3443 (1987); Better *et al.*, Science  
240:1041-1043 (1988); LoBuglio, A. *et al.*, Proc. Natl. Acad. Sci.  
USA 86:4220 (1989); LoBuglio *et al.*, International Patent  
Publication PCT/GB85/00392).

15

#### SUMMARY OF THE INVENTION

Chimeric antibody technology, such as that used in the present invention for producing chimeric antibodies specific for human tumor necrosis factor-alpha (hTNF $\alpha$ ), bridges both the  
20 hybridoma and genetic engineering technologies to provide useful products for the treatment and diagnosis of human diseases.

High affinity chimeric anti-TNF $\alpha$  mAbs of the present invention, which have potent TNF $\alpha$  neutralizing activity, including TNF $\alpha$ -neutralizing fragments thereof, are useful as  
25 therapeutic agents for TNF $\alpha$ -mediated human disease, including

cachexia, acute and chronic infectious and parasitic processes, such as bacterial, viral and fungal infections, acute and chronic inflammatory and immune processes, including autoimmune disease, alcohol-induced hepatitis, neoplastic disease and the like.

5 Preferred for therapeutic use are high affinity chimeric anti-TNF $\alpha$  antibodies according to the present invention, which neutralize human TNF- $\alpha$  with an inhibitory dose-50 (ID50) of at least about 1  $\mu$ g/ml, more preferably at least about 100 ng/ml, most preferably at least about 15 ng/ml.

10 High affinity chimeric anti-TNF $\alpha$  mAbs of the present invention, or TNF $\alpha$ -binding fragments thereof, are also particularly useful in diagnostic methods for detecting human TNF $\alpha$  in patients suspected of suffering from conditions associated with TNF $\alpha$  production, including methods wherein high  
15 affinity murine and/or chimeric anti-TNF $\alpha$  antibodies of the present invention are contacted with biological materials from a patient and an antigen-antibody reaction detected. Also included are kits for detecting TNF $\alpha$  in biological fluids comprising high affinity murine and/or chimeric anti-TNF $\alpha$  antibodies or fragments  
20 of the present invention, preferably in detectably labeled form.

The chimeric antibodies of the present invention embody a combination of the advantageous characteristics of mAbs. Like mouse mAbs, they can recognize and bind to human TNF; however, unlike mouse mAbs, the "human-specific" properties of  
25 the chimeric antibodies lower the likelihood of an immune response to the antibodies, and result in prolonged survival in

embodiment, the V region is derived from the A2 mAb. In a most preferred embodiment, the chimeric antibody is the antibody designated chimeric A2 (cA2), or a chimeric human-mouse anti-TNF mAb that competitively inhibits the binding of cA2 to TNF $\alpha$ .

5 Preferably, the chimeric antibody has an affinity, measured as an association constant ( $K_a$ ), of at least about  $1 \times 10^8$  liter/mole, more preferably, at least about  $1 \times 10^9$  liter/mole.

10 Preferably, the chimeric antibody neutralizes human TNF $\alpha$  with an ID50 of at least about 1  $\mu$ g/ml, more preferably at least about 100 ng/ml, most preferably at least about 15 ng/ml.

In one embodiment the chimeric antibody is in detectably labeled form.

The present invention is further directed to a  
15 polynucleotide molecule comprising:

(a) a first nucleotide sequence encoding at least a part of the variable region of an immunoglobulin chain, either a heavy chain or a light chain, having specificity to human TNF $\alpha$ ; and

20 (b) a second nucleotide sequence encoding at least a part of the constant region of a human immunoglobulin chain, either a heavy chain or a light chain,

both the sequences in operable linkage with each other, wherein  
25 the polynucleotide molecule encodes a protein chain capable of yielding an antibody with high affinity binding to human TNF $\alpha$ .

The first and second nucleotide sequences may be either genomic DNA or cDNA sequences.

Preferably, the variable region of the polynucleotide molecule is of murine origin. In one embodiment it is derived from a murine mAb or murine hybridoma. In a most preferred embodiment, it is derived from the murine A2 hybridoma that produces the mAb A2 or from a murine hybridoma that produces a murine mAb that competitively inhibits the binding of mAb A2 to human TNFa.

10 In a preferred embodiment, the polynucleotide molecule is a recombinant DNA molecule. This molecule may be in double stranded DNA form. Included in the present invention is the molecule as an expression vehicle, such as a plasmid.

The present invention is also directed to a host transformed or transfected with the recombinant DNA polynucleotide molecule, preferably a eukaryotic host, in particular a mammalian cell such as a non-secreting human myeloma cell or other mammalian cell of B lymphocyte lineage.

The present invention includes a process for preparing a chimeric antibody comprising: (a) culturing a host capable of expressing the chimeric heavy and light chain wherein the heavy and light chain each has at least part of a human constant region and at least part of a non-human variable region having specificity to human TNFa; (b) expressing the chimeric antibody; and (c) recovering the chimeric antibody from the culture. In a more preferred process, a mammalian cell capable of

Figure 8 provides schematic diagrams of the plasmids used for expression of the chimeric H (pA2HG1apgpt) and L (pA2HuKapgpt) chains of the chimeric A2 antibody.

Figure 9 is a graph showing results of a cross-blocking epitope ELISA with murine A2 (mA2) and chimeric (cA2) antibody competitors.

Figure 10 is a graph of a Scatchard analysis of  $^{125}\text{I}$ -labelled mAb A2 (mA2) and chimeric A2 (cA2) binding to recombinant human TNF $\alpha$  immobilized on a microtiter plate. Each Ka value was calculated from the average of two independent determinations.

Figure 11 is a graph showing neutralization of TNF cytotoxicity by chimeric A2. The control is a chimeric mouse/human IgG1 anti-platelet mAb (7E3) reacting with natural human TNF. Average absorbance values for controls were: no TNF added = 1.08; natural TNF, no Ab = 0.290; and recombinant TNF, no Ab = 0.500.

Figure 12 is a graph showing in vitro neutralization of TNF-induced ELAM-1 expression by chimeric A2. The control is a chimeric mouse/human IgG1 anti-CD4 antibody.

#### DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS

The present invention provides antibodies, including monoclonal and chimeric antibodies that are specific for, and capable of binding with high affinity to, human TNF $\alpha$  and which

can be used for diagnostic and therapeutic purposes in subjects having diseases or conditions associated with the presence of a substance reactive with anti-TNF antibody, in particular hTNF $\alpha$ , in amounts exceeding those present in a normal healthy subject.

5 The chimeric antibodies preferably contain mouse V regions which recognize an epitope of TNF, most preferably an epitope which is a "neutralizing epitope."

Preferred are high affinity human-murine chimeric anti-TNF $\alpha$  antibodies that have potent neutralizing activity against human TNF $\alpha$ . Since circulating concentrations of TNF tend to be

10 extremely low, in the range of about 10 pg/ml in non-septic individuals, and reaching about 50 pg/ml in septic patients and above 100 pg/ml in the sepsis syndrome (Hammerle, A.F. *et al.*, 1989, *supra*) or may be only be detectable at sites of TNF-

15 mediated pathology, it is preferred to use high affinity and/or potent TNF-neutralizing antibodies for both TNF immunoassays and therapy of TNF-mediated disease. Such antibodies will preferably have an affinity for hTNF $\alpha$ , expressed as  $K_a$ , of at least  $10^8$  M $^{-1}$ , more preferably, at least  $10^9$  M $^{-1}$ .

20 Preferred for human therapeutic use are high affinity chimeric antibodies with potent TNF $\alpha$ -neutralizing activity, according to the present invention, that block TNF-induced IL-6 secretion. Also preferred for human therapeutic uses are such high affinity chimeric anti-TNF $\alpha$  antibodies that block TNF-

25 induced procoagulant activity, including blocking of TNF-induced

expression of cell adhesion molecules such as ELAM-1 and ICAM-1 and blocking of TNF mitogenic activity.

Preferred anti-TNF mAbs are those which will competitively inhibit the binding to human TNF $\alpha$  of anti-TNF $\alpha$  murine mAb A2, chimeric mAb cA2, or an antibody having substantially the same specific binding characteristics. The preferred antibodies of the present invention are A2 and cA2. Preferred methods for determining mAb specificity and affinity by competitive inhibition can be found in Muller, R., Meth. Enzymol. 92:589-601 (1983), which is hereby incorporated by reference. Murine mAb A2 is produced by a cell line designated c134A. Chimeric antibody cA2 is produced by a cell line designated c168A.

Cell line c134A is deposited as a research cell bank in the Centocor Cell Biology Services Depository, and cell line c168A(RCB) is deposited as a research cell bank in the Centocor Corporate Cell Culture Research and Development Depository, both at Centocor, 200 Great Valley Parkway, Malvern, Pennsylvania, 19355. The c168A cell line is also deposited at Centocor BV, Leiden, The Netherlands.

Furthermore, c168A was deposited as of the filing date of the present application at the American Type Culture Collection, Rockville, Maryland, as a "Culture Safe Deposit."

The term "epitope" is meant to refer to that portion of any molecule capable of being recognized by and bound by an antibody. Epitopes usually consist of chemically active surface

groupings of molecules such as amino acids or sugar side chains and have specific three dimensional structural characteristics as well as specific charge characteristics. By "neutralizing epitope" is intended an epitope, which, when bound by an antibody, results in loss of biological activity of the molecule or organism containing the epitope.

An "antigen" is a molecule or a portion of a molecule capable of being bound by an antibody which is additionally capable of inducing an animal to produce antibody capable of binding to an epitope of that antigen. An antigen may have one or more than one epitope. The specific reaction referred to above is meant to indicate that the antigen will react, in a highly selective manner, with its corresponding antibody and not with the multitude of other antibodies which may be evoked by other antigens.

The term "antibody" is meant to include both intact molecules as well as fragments and derivative thereof. Fragments include, for example, Fab, Fab', F(ab')<sub>2</sub> and Fv, which are capable of binding antigen. These fragments lack the Fc fragment of intact antibody, clear more rapidly from the circulation, and may have less non-specific tissue binding than an intact antibody (Wahl et al., J. Nucl. Med. 24:316-325 (1983)). These fragments are produced from intact antibodies using methods well known in the art, for example by proteolytic cleavage with enzymes such as papain (to produce Fab fragments) or pepsin (to produce F(ab')<sub>2</sub> fragments).



In a preferred embodiment, the antibody is a monoclonal antibody designated A2. In another preferred embodiment, the antibody is a chimeric antibody which recognizes an epitope recognized by A2. In a most preferred embodiment, the antibody is a chimeric antibody designated as chimeric A2 (cA2).

The chimeric antibodies of the invention comprise individual chimeric heavy (H) and light (L) immunoglobulin chains. The chimeric H chain comprises an antigen binding region derived from the H chain of a non-human antibody specific for TNF, which is linked to at least a portion of a human H chain C region (C<sub>H</sub>).

A chimeric L chain according to the present invention, comprises an antigen binding region derived from the L chain of a non-human antibody specific for TNF, linked to at least a portion of a human L chain C region (C<sub>L</sub>).

15 As used herein, the term "antigen binding region" refers to that portion of an antibody molecule which contains the amino acid residues that interact with an antigen and confer on the antibody its specificity and affinity for the antigen. The antibody region includes the "framework" amino acid residues  
20 necessary to maintain the proper conformation of the antigen-binding residues.

As used herein, the term "chimeric antibody" includes monovalent, divalent or polyvalent immunoglobulins. A monovalent chimeric antibody is a dimer (HL) formed by a chimeric H chain associated through disulfide bridges with a chimeric L chain. A 25 divalent chimeric antibody is tetramer (H<sub>2</sub>L<sub>2</sub>) formed by two HL

dimers associated through at least one disulfide bridge. A polyvalent chimeric antibody can also be produced, for example, by employing a C<sub>H</sub> region that aggregates (e.g., from an IgM H chain, or  $\mu$  chain).

- 5           The invention also provides for "derivatives" of the mouse mAbs or the chimeric antibodies, which term includes those proteins encoded by truncated or modified genes to yield molecular species functionally resembling the immunoglobulin fragments. The modifications include, but are not limited to,
- 10   addition of genetic sequences coding for cytotoxic proteins such as plant and bacterial toxins. The fragments and derivatives can be produced from any of the hosts of this invention.

- Antibodies, fragments or derivatives having chimeric H chains and L chains of the same or different V region binding
- 15   specificity, can be prepared by appropriate association of the individual polypeptide chains, as taught, for example by Sears et al., Proc. Natl. Acad. Sci. USA 72:353-357 (1975). With this approach, hosts expressing chimeric H chains (or their derivatives) are separately cultured from hosts expressing
- 20   chimeric L chains (or their derivatives), and the immunoglobulin chains are separately recovered and then associated.
- Alternatively, the hosts can be co-cultured and the chains allowed to associate spontaneously in the culture medium, followed by recovery of the assembled immunoglobulin, fragment or
- 25   derivative.



may be derived from other animal species, in particular rodents such as rat or hamster.

The second fusion partner, which provides the immortalizing function, may be lymphoblastoid cell or a plasmacytoma or myeloma cell, which is not itself an antibody producing cell, but is malignant. Preferred fusion partner cells include the hybridoma SP2/0-Ag14, abbreviated as SP2/0 (ATCC CRL1581) and the myeloma P3X63Ag8 (ATCC TIB9), or its derivatives (see: Hartlow, E. et al., Antibodies: A Laboratory Manual, Cold Spring Harbor Laboratory Press, Cold Spring Harbor, NY, 1988)).

Murine hybridomas which produce mAb specific for human TNF $\alpha$  are formed by the fusion of a mouse fusion partner cell, such as SP2/0, and spleen cells from mice immunized against purified hTNF $\alpha$ , recombinant hTNF $\alpha$ , natural or synthetic TNF peptides, or other biological preparations containing TNF. To immunize the mice, a variety of different conventional protocols may be followed. For example, mice may receive primary and boosting immunizations of TNF.

The cell fusions are accomplished by standard procedures well known to those skilled in the field of immunology (Kohler and Milstein, Nature 256:495-497 (1975) and U.S. Patent No. 4,376,110; Hartlow, E. et al., supra; Campbell, A., "Monoclonal Antibody Technology," In: Laboratory Techniques in Biochemistry and Molecular Biology, Volume 13 (Burdon, R., et al., eds.), Elsevier, Amsterdam (1984); Kennett et al.,

Monoclonal Antibodies (Kennett et al., eds. pp. 365-367, Plenum Press, NY, 1980); de St. Groth, S.F., et al., J. Immunol. Meth. 35: 1-21 (1980); Galfre, G. et al., Methods Enzymol. 71:3-46 (1981); Goding, J.W. 1987. Monoclonal Antibodies: Principles and Practice. 2nd ed. Academic Press, London, 1987) ;

Fusion partner cell lines and methods for fusing and selecting hybridomas and screening for mAbs are well known in the art (Hartlow, E. et al., supra; Kawamoto, T. et al., Meth. Enzymol. 121:266-277 (1986); Kearney, J.F. et al., J. Immunol. 123:1548-1550 (1979); Kilmartin, J.V. et al., J. Cell Biol. 93:576-582 (1982); Kohler, G. et al., Eur. J. Immunol. 6:292-295 (1976); Lane, D.P. et al., J. Immunol. Meth. 47:303-307 (1981); Mueller, U.W. et al., J. Immunol. Meth. 87:193-196 (1986); Pontecorvo, G., Somatic Cell Genet. 1:397-400 (1975); Sharo, J., et al., Proc. Natl. Acad. Sci. USA 76:1420-1424 (1979); Shulman, M. et al., Nature 276:269-270 (1978); Springer, T.A. (ed), Hybridoma Technology in the Biosciences and Medicine, Plenum Press, New York, 1985; and Taggart, R.T. et al., Science 219:1228-1230 (1982)).

The hTNF $\alpha$ -specific murine or chimeric mAb of the present invention may be produced in large quantities by injecting hybridoma or transfectoma cells secreting the antibody into the peritoneal cavity of mice and, after appropriate time, harvesting the ascites fluid which contains a high titer of the mAb, and isolating the mAb therefrom. For such in vivo production of the mAb with a non-murine hybridoma (e.g., rat or

human), hybridoma cells are preferably grown in irradiated athymic nude mice.

Alternatively, the antibodies may be produced by culturing hybridoma or transfectoma cells in vitro and isolating  
5 secreted mAb from the cell culture medium.

Human genes which encode the constant (C) regions of the chimeric antibodies of the present invention were derived from a human fetal liver library. Human C regions genes may be derived from any human cell including those which express and  
10 produce human immunoglobulins. The human C<sub>H</sub> region can be derived from any of the known classes or isotypes of human H chains, including gamma,  $\mu$ ,  $\alpha$ ,  $\delta$  or  $\epsilon$ , and subtypes thereof, such as G1, G2, G3 and G4. Since the H chain isotype is responsible for the various effector functions of an antibody, the choice of  
15 C<sub>H</sub> region will be guided by the desired effector functions, such as complement fixation, or activity in antibody-dependent cellular cytotoxicity (ADCC). Preferably, the C<sub>H</sub> region is derived from gamma 1 (IgG1), gamma 3 (IgG3), gamma 4 (IgG4), or  $\mu$  (IgM).

20 The human C<sub>L</sub> region can be derived from either human L chain isotype, kappa or lambda.

Genes encoding human immunoglobulin C regions are obtained from human cells by standard cloning techniques (Sambrook, J. et al. (Molecular Cloning: A Laboratory Manual,  
25 2nd Edition, Cold Spring Harbor Press, Cold Spring Harbor, NY (1989)). Human C region genes are readily available from known

clones containing genes representing the two classes of L chains,  
the five classes of H chains and subclasses thereof. Chimeric  
antibody fragments, such as  $F(ab')_2$  and Fab, can be prepared by  
designing a chimeric H chain gene which is appropriately  
5 truncated. For example, a chimeric gene encoding an H chain  
portion of an  $F(ab')_2$  fragment would include DNA sequences  
encoding the  $CH_1$  domain and hinge region of the H chain, followed  
by a translational stop codon to yield the truncated molecule.

Generally, the chimeric antibodies of the present  
10 invention are produced by cloning DNA segments encoding the H and  
L chain antigen-binding regions of a TNF-specific antibody,  
preferably non-human, and joining these DNA segments to DNA  
segments encoding human  $C_H$  and  $C_L$  regions, respectively, to  
produce chimeric immunoglobulin-encoding genes.

15 Thus, in a preferred embodiment, a fused gene is  
created which comprises a first DNA segment that encodes at least  
the antigen-binding region of non-human origin, such as a  
functionally rearranged V region with joining (J) segment, linked  
to a second DNA segment encoding at least a part of a human C  
20 region.

The DNA encoding the antibody-binding region may be  
genomic DNA or cDNA. A convenient alternative to the use of  
chromosomal gene fragments as the source of DNA encoding the  
murine V region antigen-binding segment is the use of cDNA for  
25 the construction of chimeric immunoglobulin genes, as reported by  
Liu et al. (Proc. Natl. Acad. Sci., USA 84:3439 (1987) and J.

Immunology 139:3521 (1987), which references are hereby

incorporated by reference. The use of cDNA requires that gene expression elements appropriate for the host cell be combined with the gene in order to achieve synthesis of the desired

5 protein. The use of cDNA sequences is advantageous over genomic sequences (which contain introns), in that cDNA sequences can be expressed in bacteria or other hosts which lack appropriate RNA splicing systems.

Therefore, in an embodiment utilizing cDNA encoding the  
10 antibody V region, the method of producing the chimeric antibody involves several steps, outlined below:

1. Isolation of messenger RNA (mRNA) from the cell line producing the monoclonal antibody, cloning and cDNA production therefrom;
- 15 2. Preparation of a full length cDNA library from purified mRNA from which the appropriate V region gene segments of the L and H chain genes can be: (i) identified with appropriate probes, (ii) sequenced, and (iii) made compatible with a C gene segment;
- 20 3. Preparation of C region gene segments by cDNA preparation and cloning;
4. Construction of complete H or L chain-coding sequences by linkage of the cloned specific V region gene segments to cloned human C region gene, as described above;
- 25 5. Expression and production of chimeric L and H chains in selected hosts, including prokaryotic and eukaryotic cells.



4100300

One common feature of all immunoglobulin H and L chain genes and their encoded mRNAs is the J region. H and L chain J regions have different sequences, but a high degree of sequence homology exists (greater than 80%) among each group, especially near the C region. This homology is exploited in this method and consensus sequences of H and L chain J regions may be used to design oligonucleotides for use as primers for introducing useful restriction sites into the J region for subsequent linkage of V region segments to human C region segments.

10 C region cDNA vectors prepared from human cells can be modified by site-directed mutagenesis to place a restriction site at the analogous position in the human sequence. For example, one can clone the complete human kappa chain C ( $C_k$ ) region and the complete human gamma-1 C region ( $C_{\text{gamma-1}}$ ). In 15 this case, the alternative method based upon genomic C region clones as the source for C region vectors would not allow these genes to be expressed in bacterial systems where enzymes needed to remove intervening sequences are absent. Cloned V region segments are excised and ligated to L or H chain C region 20 vectors. Alternatively, the human  $C_{\text{gamma-1}}$  region can be modified by introducing a termination codon thereby generating a gene sequence which encodes the H chain portion of an Fab molecule. The coding sequences with linked V and C regions are then transferred into appropriate expression vehicles for expression 25 in appropriate hosts, prokaryotic or eukaryotic.

Two coding DNA sequences are said to be "operably linked" if the linkage results in a continuously translatable sequence without alteration or interruption of the triplet reading frame. A DNA coding sequence is operably linked to a gene expression element if the linkage results in the proper function of that gene expression element to result in expression of the coding sequence.

Expression vehicles include plasmids or other vectors. Preferred among these are vehicles carrying a functionally complete human  $C_H$  or  $C_L$  chain sequence having appropriate restriction sites engineered so that any  $V_H$  or  $V_L$  chain sequence with appropriate cohesive ends can be easily inserted therein. Human  $C_H$  or  $C_L$  chain sequence-containing vehicles thus serve as intermediates for the expression of any desired complete H or L chain in any appropriate host.

A chimeric mouse-human antibody will typically be synthesized from genes driven by the chromosomal gene promoters native to the mouse H and L chain V regions used in the constructs; splicing usually occurs between the splice donor site in the mouse J region and the splice acceptor site preceding the human C region and also at the splice regions that occur within the human  $C_H$  region; polyadenylation and transcription termination occur at native chromosomal sites downstream of the human coding regions.

Gene expression elements useful for the expression of cDNA genes include: (a) viral transcription promoters and their

enhancer elements, such as the SV40 early promoter (Okayama, H.  
et al., Mol. Cell. Biol. 1:280 (1983)), Rous sarcoma virus LTR  
(Gorman, C. et al., Proc. Natl. Acad. Sci. USA 79:6777 (1982)),  
and Moloney murine leukemia virus LTR (Grosschedl, R. et al., Cell  
5 41:885 (1985)); (b) splice regions and polyadenylation sites  
such as those derived from the SV40 late region (Okayama et al.,  
supra); and (c) polyadenylation sites such as in SV40 (Okayama  
et al., supra).

Immunoglobulin cDNA genes may be expressed as described  
10 by Liu et al., supra, and Weidle et al., Gene 51:21 (1987),  
using as expression elements the SV40 early promoter and its  
enhancer, the mouse immunoglobulin H chain promoter enhancers,  
SV40 late region mRNA splicing, rabbit  $\beta$ -globin intervening  
sequence, immunoglobulin and rabbit  $\beta$ -globin polyadenylation  
15 sites, and SV40 polyadenylation elements. For immunoglobulin  
genes comprised of part cDNA, part genomic DNA (Whittle et al.,  
Protein Engineering 1:499 (1987)), the transcriptional promoter  
is human cytomegalovirus, the promoter enhancers are  
cytomegalovirus and mouse/human immunoglobulin, and mRNA splicing  
20 and polyadenylation regions are from the native chromosomal  
immunoglobulin sequences.

In one embodiment, for expression of cDNA genes in  
rodent cells, the transcriptional promoter is a viral-LTR  
sequence, the transcriptional promoter enhancers are either or  
25 both the mouse immunoglobulin heavy chain enhancer and the viral  
LTR enhancer, the splice region contains an intron of greater

than 31 bp, and the p lyadenylation and transcription termination regions are derived from the native chromosomal sequence corresponding to the immunoglobulin chain being synthesized. In other embodiments, cDNA sequences encoding other proteins are  
5 combined with the above-recited expression elements to achieve expression of the proteins in mammalian cells.

Each fused gene is assembled in, or inserted into, an expression vector. Recipient cells capable of expressing the chimeric immunoglobulin chain gene product are then transfected  
10 singly with a chimeric H or chimeric L chain-encoding gene, or are co-transfected with a chimeric H and a chimeric L chain gene. The transfected recipient cells are cultured under conditions that permit expression of the incorporated genes and the expressed immunoglobulin chains or intact antibodies or  
15 fragments are recovered from the culture.

In one embodiment, the fused genes encoding the chimeric H and L chains, or portions thereof, are assembled in separate expression vectors that are then used to co-transfect a recipient cell.

20 Each vector may contain two selectable genes, a first selectable gene designed for selection in a bacterial system and a second selectable gene designed for selection in a eukaryotic system, wherein each vector has a different pair of genes. This strategy results in vectors which first direct the production,  
25 and permit amplification, of the fused genes in a bacterial system. The genes so produced and amplified in a bacterial host

are subsequently used to co-transfect a eukaryotic cell, and allow selection of a co-transfected cell carrying the desired transfected genes.

Examples of selectable genes for use in a bacterial system are the gene that confers resistance to ampicillin and the gene that confers resistance to chloramphenicol. Preferred selectable genes for use in eukaryotic transfectants include the xanthine guanine phosphoribosyl transferase gene (designated gpt) and the phosphotransferase gene from Tn5 (designated neo). Selection of cells expressing gpt is based on the fact that the enzyme encoded by this gene utilizes xanthine as a substrate for purine nucleotide synthesis, whereas the analogous endogenous enzyme cannot. In a medium containing (1) mycophenolic acid, which blocks the conversion of inosine monophosphate to xanthine monophosphate, and (2) xanthine, only cells expressing the gpt gene can survive. The product of the neo blocks the inhibition of protein synthesis by the antibiotic G418 and other antibiotics of the neomycin class.

The two selection procedures can be used simultaneously or sequentially to select for the expression of immunoglobulin chain genes introduced on two different DNA vectors into a eukaryotic cell. It is not necessary to include different selectable markers for eukaryotic cells; an H and an L chain vector, each containing the same selectable marker can be co-transfected. After selection of the appropriately resistant

cells, the majority of the clones will contain integrated copies of both H and L chain vectors.

Alternatively, the fused genes encoding the chimeric H and L chains can be assembled on the same expression vector.

5 For transfection of the expression vectors and production of the chimeric antibody, the preferred recipient cell line is a myeloma cell. Myeloma cells can synthesize, assemble and secrete immunoglobulins encoded by transfected immunoglobulin genes and possess the mechanism for glycosylation of the  
10 immunoglobulin. A particularly preferred recipient cell is the Ig-non-producing myeloma cell SP2/0 (ATCC #CRL 8287). SP2/0 cells produce only immunoglobulin encoded by the transfected genes. Myeloma cells can be grown in culture or in the peritoneal cavity of a mouse, where secreted immunoglobulin can  
15 be obtained from ascites fluid. Other suitable recipient cells include lymphoid cells such as B lymphocytes of human or non-human origin, hybridoma cells of human or non-human origin, or interspecies heterohybridoma cells.

The expression vector carrying a chimeric antibody  
20 construct of the present invention may be introduced into an appropriate host cell by any of a variety of suitable means, including such biochemical means as transformation, transfection, conjugation, protoplast fusion, calcium phosphate-precipitation, and application with polycations such as diethylaminoethyl (DEAE)  
25 dextran, and such mechanical means as electroporation, direct microinjection, and microprojectile bombardment (Johnston et al.,

Science 240:1538 (1988)). A preferred way of introducing DNA into lymphoid cells is by electroporation (Potter et al., Proc. Natl. Acad. Sci. USA 81:7161 (1984); Yoshikawa, K. et al., Jpn. J. Cancer Res. 77:1122-1133). In this procedure, recipient cells  
5 are subjected to an electric pulse in the presence of the DNA to be incorporated. Typically, after transfection, cells are allowed to recover in complete medium for about 24 hours, and are then seeded in 96-well culture plates in the presence of the selective medium. G418 selection is performed using about 0.4 to  
10 0.8 mg/ml G418. Mycophenolic acid selection utilizes about 6µg/ml plus about 0.25 mg/ml xanthine. The electroporation technique is expected to yield transfection frequencies of about  $10^{-5}$  to about  $10^{-4}$  for Sp2/0 cells. In the protoplast fusion method, lysozyme is used to strip cell walls from catarrhal  
15 harboring the recombinant plasmid containing the chimeric antibody gene. The resulting spheroplasts are fused with myeloma cells with polyethylene glycol.

The chimeric immunoglobulin genes of the present invention can also be expressed in nonlymphoid mammalian cells or  
20 in other eukaryotic cells, such as yeast, or in prokaryotic cells, in particular bacteria.

Yeast provides substantial advantages over bacteria for the production of immunoglobulin H and L chains. Yeasts carry out post-translational peptide modifications including  
25 glycosylation. A number of recombinant DNA strategies now exist which utilize strong promoter sequences and high copy number

plasmids which can be used for production of the desired proteins in yeast. Yeast recognizes leader sequences of cloned mammalian gene products and secretes peptides bearing leader sequences (i.e., pre-peptides) (Hitzman, et al., 11th International  
5 Conference on Yeast, Genetics and Molecular Biology, Montpellier, France, September 13-17, 1982).

Yeast gene expression systems can be routinely evaluated for the levels of production, secretion and the stability of chimeric H and L chain proteins and assembled  
10 chimeric antibodies. Any of a series of yeast gene expression systems incorporating promoter and termination elements from the actively expressed genes coding for glycolytic enzymes produced in large quantities when yeasts are grown in media rich in glucose can be utilized. Known glycolytic genes can also  
15 provide very efficient transcription control signals. For example, the promoter and terminator signals of the phosphoglycerate kinase (PGK) gene can be utilized. A number of approaches may be taken for evaluating optimal expression plasmids for the expression of cloned immunoglobulin cDNAs in  
20 yeast (see Glover, D.M., ed., DNA Cloning, Vol. II, pp45-66, IRL Press, 1985).

Bacterial strains may also be utilized as hosts for the production of antibody molecules or antibody fragments described by this invention, E. coli K12 strains such as E. coli W3110  
25 (ATCC 27325), and other enterobacteria such as Salmonella



typhimurium or Serratia marcescens, and various Pseudomonas species may be used.

Plasmid vectors containing replicon and control sequences which are derived from species compatible with a host cell are used in connection with these bacterial hosts. The vector carries a replication site, as well as specific genes which are capable of providing phenotypic selection in transformed cells. A number of approaches may be taken for evaluating the expression plasmids for the production of chimeric antibodies or antibody chains encoded by the cloned immunoglobulin cDNAs in bacteria (see Glover, D.M., ed., DNA Cloning, Vol. I, IRL Press, 1985).

Preferred hosts are mammalian cells, grown in vitro or in vivo. Mammalian cells provide post-translational modifications to immunoglobulin protein molecules including leader peptide removal, folding and assembly of H and L chains, glycosylation of the antibody molecules, and secretion of functional antibody protein.

Mammalian cells which may be useful as hosts for the production of antibody proteins, in addition to the cells of lymphoid origin described above, include cells of fibroblast origin, such as Vero (ATCC CRL 81) or CHO-K1 (ATCC CRL 61).

Many vector systems are available for the expression of cloned H and L chain genes in mammalian cells (see Glover, D.M., ed., DNA Cloning, Vol. II, pp143-238, IRL Press, 1985).

Different approaches can be followed to obtain complete H<sub>2</sub>L<sub>2</sub>

antibodies. As discussed above, it is possible to co-express H and L chains in the same cells to achieve intracellular association and linkage of H and L chains into complete tetrameric  $H_2L_2$  antibodies. The co-expression can occur by using  
5 either the same or different plasmids in the same host. Genes for both H and L chains can be placed into the same plasmid, which is then transfected into cells, thereby selecting directly for cells that express both chains. Alternatively, cells may be transfected first with a plasmid encoding one chain, for example  
10 the L chain, followed by transfection of the resulting cell line with an H chain plasmid containing a second selectable marker. Cell lines producing  $H_2L_2$  molecules via either route could be transfected with plasmids encoding additional copies of H, L, or  
H plus L chains in conjunction with additional selectable markers  
15 to generate cell lines with enhanced properties, such as higher production of assembled  $H_2L_2$  antibody molecules or enhanced stability of the transfected cell lines.

In addition to monoclonal or chimeric anti-TNF antibodies, the present invention is also directed to an anti-  
20 idiotypic (anti-Id) antibody specific for the anti-TNF antibody of the invention. An anti-Id antibody is an antibody which recognizes unique determinants generally associated with the antigen-binding region of another antibody. The antibody specific for TNF is termed the idiotypic or Id antibody. The  
25 anti-Id can be prepared by immunizing an animal of the same species and genetic type (e.g. mouse strain) as the source of the

Id antibody with the Id antibody or the antigen-binding region thereof. The immunized animal will recognize and respond to the idiotypic determinants of the immunizing antibody and produce an anti-Id antibody. The anti-Id antibody may also be used as an  
5 "immunogen" to induce an immune response in yet another animal, producing a so-called anti-anti-Id antibody. The anti-anti-Id may be epitopically identical to the original antibody which induced the anti-Id. Thus, by using antibodies to the idiotypic determinants of a mAb, it is possible to identify other clones  
10 expressing antibodies of identical specificity.

Accordingly, mAbs generated against TNF according to the present invention may be used to induce anti-Id antibodies in suitable animals, such as BALB/c mice. Spleen cells from such immunized mice can be used to produce anti-Id hybridomas  
15 secreting anti-Id mAbs. Further, the anti-Id mAbs can be coupled to a carrier such as keyhole limpet hemocyanin (KLH) and used to immunize additional BALB/c mice. Sera from these mice will contain anti-anti-Id antibodies that have the binding properties of the original mAb specific for a TNF epitope.

20 The antibodies, fragments and derivatives of the present invention are useful for treating a subject having a disease or condition associated with levels of a substance reactive with an anti-TNF antibody, in particular TNF, in excess of the levels present in a normal healthy subject. Such diseases  
25 include, but are not limited to, sepsis syndrome, including cachexia, circulatory collapse and shock resulting from acute or

chr nic bacterial infection, acute and chronic parasitic or infectious processes, including bacterial, viral and fungal infections, acute and chronic immune and autoimmune diseases, such as systemic lupus erythematosus and rheumatoid arthritis, 5 alcohol-induced hepatitis, chronic inflammatory diseases such as sarcoidosis and Crohn's disease, vascular inflammatory diseases such as disseminated intravascular coagulation, graft-versus-host disease, Kawasaki's disease and malignant diseases involving TNF-secreting tumors.

10 Such treatment comprises parenterally administering a single or multiple doses of the antibody, fragment or derivative. Preferred for human pharmaceutical use are high affinity potent hTNFa-neutralizing chimeric antibodies of this invention.

Monoclonal antibodies may be administered by any means: 15 that enables the active agent to reach the agent's site of action in the body of a mammal. In the case of the antibodies of this invention, the primary focus is the ability to reach and bind with TNF released by monocytes and macrophages. Because proteins are subject to being digested when administered orally, 20 parenteral administration, i.e., intravenous, subcutaneous, intramuscular, would ordinarily be used to optimize absorption.

Monoclonal antibodies may be administered either as individual therapeutic agents or in combination with other therapeutic agents. They can be administered alone, but are 25 generally administered with a pharmaceutical carrier selected on

4 18 02 02

the basis of the chosen route of administration and standard pharmaceutical practice.

The dosage administered will, of course, vary depending upon known factors such as the pharmacodynamic characteristics of the particular agent, and its mode and route of administration; age, health, and weight of the recipient; nature and extent of symptoms, kind of concurrent treatment, frequency of treatment, and the effect desired. Usually a daily dosage of active ingredient can be about 0.1 to 100 milligrams per kilogram of body weight. Ordinarily 0.5 to 50, and preferably 1 to 10 milligrams per kilogram per day given in divided doses 1 to 6 times a day or in sustained release form is effective to obtain desired results.

Dosage forms (composition) suitable for internal administration generally contain from about 1 milligram to about 500 milligrams of active ingredient per unit. In these pharmaceutical compositions the active ingredient will ordinarily be present in an amount of about 0.5-95% by weight based on the total weight of the composition.

For parenteral administration, the antibody can be formulated as a solution, suspension, emulsion or lyophilized powder in association with a pharmaceutically acceptable parenteral vehicle. Examples of such vehicles are water, saline, Ringer's solution, dextrose solution, and 5% human serum albumin. Liposomes and nonaqueous vehicles such as fixed oils may also be used. The vehicle or lyophilized powder may contain additives

that maintain isotonicity (e.g., sodium chloride, mannitol) and chemical stability (e.g., buffers and preservatives). The formulation is sterilized by commonly used techniques.

Suitable pharmaceutical carriers are described in the most recent edition of Remington's Pharmaceutical Sciences, A. Osol, a standard reference text in this field.

For example, a parenteral composition suitable for administration by injection is prepared by dissolving 1.5% by weight of active ingredient in 0.9% sodium chloride solution.

The antibodies of this invention can be adapted for therapeutic efficacy by virtue of their ability to mediate antibody-dependent cellular cytotoxicity (ADCC) and/or complement-dependent cytotoxicity (CDC) against cells having TNF associated with their surface. For these activities, either an endogenous source or an exogenous source of effector cells (for ADCC) or complement components (for CDC) can be utilized. The chimeric antibodies of this invention, their fragments, and derivatives can be used therapeutically as immunoconjugates (see for review: Dillman, R.O., Ann. Int. Med. 111:592-603 (1989)). They can be coupled to cytotoxic proteins, including, but not limited to Ricin-A, Pseudomonas toxin, Diphtheria toxin, and TNF. Toxins conjugated to antibodies or other ligands, are known in the art (see, for example, Olsnes, S. et al., Immunol. Today 10:291-295 (1989)). Plant and bacterial toxins typically kill cells by disrupting the protein synthetic machinery.

The antibodies of this invention can be conjugated to additional types of therapeutic moieties including, but not limited to, radionuclides, cytotoxic agents and drugs. Examples of radionuclides which can be coupled to antibodies-and-  
5 delivered in vivo to sites of antigen include  $^{212}\text{Bi}$ ,  $^{131}\text{I}$ ,  $^{186}\text{Re}$ , and  $^{90}\text{Y}$ , which list is not intended to be exhaustive. The radionuclides exert their cytotoxic effect by locally irradiating the cells, leading to various intracellular lesions, as is known in the art of radiotherapy.

10 Cytotoxic drugs which can be conjugated to antibodies and subsequently used for in vivo therapy include, but are not limited to, daunorubicin, doxorubicin, methotrexate, and Mitomycin C. Cytotoxic drugs interfere with critical cellular processes including DNA, RNA, and protein synthesis. For a  
15 fuller exposition of these classes of drugs which are known in the art, and their mechanisms of action, see Goodman, A.G., et al., Goodman and Gilman's THE PHARMACOLOGICAL BASIS OF THERAPEUTICS, 7th Ed., Macmillan Publishing Co., 1985.

The antibodies of this invention may be advantageously  
20 utilized in combination with other monoclonal or chimeric antibodies, or with lymphokines or hemopoietic growth factors, etc., which serve to increase the number or activity of effector cells which interact with the antibodies.

The antibodies, fragments or derivatives of this  
25 invention may also be used in combination with TNF therapy to block undesired side effects of TNF. Recent approaches to cancer

therapy have included direct administration of TNF to cancer patients or immunotherapy of cancer patients with lymph kine activated killer (LAK) cells (Rosenberg et al., New Eng. J. Med. 313:1485-1492 (1985)) or tumor infiltrating lymphocytes (TIL) (Kurnick et al., Clin. Immunol. Immunopath. 38:367-380 (1986); Kradin et al., Cancer Immunol. Immunother. 24:76-85 (1987); Kradin et al., Transplant. Proc. 20:336-338 (1988)). Trials are currently underway using modified LAK cells or TIL which have been transfected with the TNF gene to produce large amounts of TNF. Such therapeutic approaches are likely to be associated with a number of undesired side effects caused by the pleiotropic actions of TNF which were described above. According to the present invention, these side effects can be reduced by concurrent treatment of a subject receiving TNF or cells producing large amounts of TIL with the antibodies, fragments or derivatives of the present invention. Effective doses are as described above. The dose level will require adjustment according to the dose of TNF or TNF-producing cells administered, in order to block side effects without blocking the main anti-tumor effect of TNF. One of ordinary skill in the art will know how to determine such doses without undue experimentation.

The chimeric antibodies, fragments, or derivatives of this invention, attached to a solid support, can be used to remove TNF from fluids or tissue or cell extracts. In a preferred embodiment, they are used to remove TNF from blood or blood plasma products. In another preferred embodiment, the



chimeric antibodies are advantageously used in extracorporeal immunoadsorbent devices, which are known in the art (see, for example, Seminars in Hematology, Vol. 26 (2 Suppl. 1) (1989)).

Patient blood or other body fluid is exposed to the attached  
 5 antibody, resulting in partial or complete removal of circulating TNF (free or in immune complexes), following which the fluid is returned to the body. This immunoadsorption can be implemented in a continuous flow arrangement, with or without interposing a cell centrifugation step. See, for example,  
 10 Terman, D.S. et al., J. Immunol. 117:1971-1975 (1976).

The present invention also provides the above antibodies, fragments and derivatives, detectably labeled, as described below, for use in diagnostic methods for detecting TNF $\alpha$  in patients known to be or suspected of having a TNF $\alpha$ -mediated  
 15 condition.

The antibodies of the present invention are useful for immunoassays which detect or quantitate TNF, or anti-TNF antibodies, in a sample. An immunoassay for TNF typically comprises incubating a biological sample in the presence of a  
 20 detectably labeled high affinity antibody of the present invention capable of selectively binding to TNF, and detecting the labeled antibody which is bound in a sample. Various clinical immunoassay procedures are described in Immunoassays for the 80's, A. Voller et al., eds., University Park, 1981.

25 Thus, in this aspect of the invention, the antibody or a biological sample may be added to nitrocellulose, or other

solid support which is capable of immobilizing cells, cell particles or soluble proteins. The support may then be washed with suitable buffers followed by treatment with the detectably labeled TNF-specific antibody. The solid phase support may then  
 5 be washed with the buffer a second time to remove unbound antibody. The amount of bound label on said solid support may then be detected by conventional means.

By "solid phase support" or "carrier" is intended any support capable of binding antigen or antibodies. Well-known  
 10 supports or carriers, include glass, polystyrene, polypropylene, polyethylene, dextran, nylon, amylases, natural and modified celluloses, polyacrylamides, agaroses, and magnetite. The nature of the carrier can be either soluble to some extent or insoluble for the purposes of the present invention. The support material  
 15 may have virtually any possible structural configuration so long as the coupled molecule is capable of binding to TNF or an anti-TNF antibody. Thus, the support configuration may be spherical, as in a bead, or cylindrical, as in the inside surface of a test tube, or the external surface of a rod. Alternatively, the  
 20 surface may be flat such as a sheet, test strip, etc. Preferred supports include polystyrene beads. Those skilled in the art will know many other suitable carriers for binding antibody or antigen, or will be able to ascertain the same by use of routine experimentation.

25 The binding activity of a given lot of anti-TNF antibody may be determined according to well known methods.

Those skilled in the art will be able to determine operative and optimal assay conditions for each determination by employing routine experimentation.

One of the ways in which the TNF-specific antibody can be detectably labeled is by linking the same to an enzyme and use in an enzyme immunoassay (EIA), or enzyme-linked immunosorbent assay (ELISA). This enzyme, when subsequently exposed to its substrate, will react with the substrate generating a chemical moiety which can be detected, for example, by spectrophotometric, fluorometric or by visual means. Enzymes which can be used to detectably label the TNF-specific antibodies of the present invention include, but are not limited to, malate dehydrogenase, staphylococcal nuclease, delta-5-steroid isomerase, yeast alcohol dehydrogenase, alpha-glycerophosphate dehydrogenase, triose phosphate isomerase, horseradish peroxidase, alkaline phosphatase, asparaginase, glucose oxidase, beta-galactosidase, ribonuclease, urease, catalase, glucose-6-phosphate dehydrogenase, glucoamylase and acetylcholinesterase.

By radioactively labeling the TNF-specific antibodies, it is possible to detect TNF through the use of a radioimmunoassay (RIA) (see, for example, Work, T.S., et al., Laboratory Techniques and Biochemistry in Molecular Biology, North Holland Publishing Company, N.Y. (1978)). The radioactive isotope can be detected by such means as the use of a gamma counter or a scintillation counter or by autoradiography. Isotopes which are particularly useful for the purpose of the

present invention are:  $^3\text{H}$ ,  $^{125}\text{I}$ ,  $^{131}\text{I}$ ,  $^{35}\text{S}$ ,  $^{14}\text{C}$ , and, preferably,  $^{125}\text{I}$ .

It is also possible to label the TNF-specific antibodies with a fluorescent compound. When the fluorescently labeled antibody is exposed to light of the proper wave length, its presence can then be detected due to fluorescence. Among the most commonly used fluorescent labelling compounds are fluorescein isothiocyanate, rhodamine, phycoerythrin, phycocyanin, allophycocyanin,  $\alpha$ -phthaldehyde and fluorescamine.

The TNF-specific antibodies can also be detectably labeled using fluorescence-emitting metals such as  $^{152}\text{Eu}$ , or others of the lanthanide series. These metals can be attached to the TNF-specific antibody using such metal chelating groups as diethylenetriaminepentaacetic acid (DTPA) or ethylenediamine-tetraacetic acid (EDTA).

The TNF-specific antibodies also can be detectably labeled by coupling to a chemiluminescent compound. The presence of the chemiluminescently labeled antibody is then determined by detecting the presence of luminescence that arises during the course of a chemical reaction. Examples of particularly useful chemiluminescent labeling compounds are luminol, isoluminol, theromatic acridinium ester, imidazole, acridinium salt and oxalate ester.

Likewise, a bioluminescent compound may be used to label the TNF-specific antibody, fragment or derivative of the present invention. Bioluminescence is a type of

031891

SL:VILCEK3.APP

chemiluminescence found in biological systems in which a catalytic protein increases the efficiency of the chemiluminescent reaction. The presence of a bioluminescent protein is determined by detecting the presence of luminescence. Important bioluminescent compounds for purposes of labeling are luciferin, luciferase and aequorin.

Detection of the TNF-specific antibody, fragment or derivative may be accomplished by a scintillation counter, for example, if the detectable label is a radioactive gamma emitter, or by a fluorometer, for example, if the label is a fluorescent material. In the case of an enzyme label, the detection can be accomplished by colorimetric methods which employ a substrate for the enzyme. Detection may also be accomplished by visual comparison of the extent of enzymatic reaction of a substrate in comparison with similarly prepared standards.

For the purposes of the present invention, the TNF which is detected by the above assays may be present in a biological sample. Any sample containing TNF can be used. Preferably, the sample is a biological fluid such as, for example, blood, serum, lymph, urine, inflammatory exudate, cerebrospinal fluid, amniotic fluid, a tissue extract or homogenate, and the like. However, the invention is not limited to assays using only these samples, it being possible for one of ordinary skill in the art to determine suitable conditions which allow the use of other samples.

In situ detection may be accomplished by removing a histological specimen from a patient, and providing the combination of labeled antibodies of the present invention to such a specimen. The antibody (or fragment) is preferably provided by applying or by overlaying the labeled antibody (or fragment) to a biological sample. Through the use of such a procedure, it is possible to determine not only the presence of TNF but also the distribution of TNF in the examined tissue. Using the present invention, those of ordinary skill will readily perceive that any of a wide variety of histological methods (such as staining procedures) can be modified in order to achieve such in situ detection.

The antibody, fragment or derivative of the present invention may be adapted for utilization in an immunometric assay, also known as a "two-site" or "sandwich" assay. In a typical immunometric assay, a quantity of unlabeled antibody (or fragment of antibody) is bound to a solid support that is insoluble in the fluid being tested and a quantity of detectably labeled soluble antibody is added to permit detection and/or quantitation of the ternary complex formed between solid-phase antibody, antigen, and labeled antibody.

Typical, and preferred, immunometric assays include "forward" assays in which the antibody bound to the solid phase is first contacted with the sample being tested to extract the TNF from the sample by formation of a binary solid phase antibody-TNF complex. After a suitable incubation period, the

solid support is washed to remove the residue of the fluid sample, including unreacted TNF, if any, and then contacted with the solution containing a known quantity of labeled antibody (which functions as a "reporter molecule"). After a second  
5 incubation period to permit the labeled antibody to complex with the TNF bound to the solid support through the unlabeled antibody, the solid support is washed a second time to remove the unreacted labeled antibody. This type of forward sandwich assay may be a simple "yes/no" assay to determine whether TNF is  
10 present or may be made quantitative by comparing the measure of labeled antibody with that obtained for a standard sample containing known quantities of TNF. Such "two-site" or "sandwich" assays are described by Wide (Radioimmune Assay Method, Kirkham, ed., E. & S. Livingstone, Edinburgh, 1970, pp. 199-206).

15 Other type of "sandwich" assays, which may also be useful with TNF, are the so-called "simultaneous" and "reverse" assays. A simultaneous assay involves a single incubation step wherein the antibody bound to the solid support and labeled antibody are both added to the sample being tested at the same  
20 time. After the incubation is completed, the solid support is washed to remove the residue of fluid sample and uncomplexed labeled antibody. The presence of labeled antibody associated with the solid support is then determined as it would be in a conventional "forward" sandwich assay.

25 In the "reverse" assay, stepwise addition first of a solution of labeled antibody to the fluid sample followed by the

addition of unlabeled antibody bound to a solid support after a  
suitable incubation period, is utilized. After a second  
incubation, the solid phase is washed in conventional fashion to  
free it of the residue of the sample being tested and the  
5 solution of unreacted labeled antibody. The determination of  
labeled antibody associated with a solid support is then  
determined as in the "simultaneous" and "forward" assays. In one  
embodiment, a combination of antibodies of the present invention  
specific for separate epitopes may be used to construct a  
10 sensitive three-site immunoradiometric assay.

Having now generally described the invention, the same  
will be further understood by reference to certain specific  
examples which are included herein for purposes of illustration;  
only and are not intended to be limiting unless otherwise  
15 specified.

#### EXAMPLE I

##### Production of A2, a Mouse Anti-Human TNF mAb

To facilitate clinical study of TNF mAb a high-affinity  
potent neutralizing mouse anti-human TNF IgG1 mAb designated A2  
20 was produced. Female BALB/c mice, 10 weeks old, were obtained  
from the Jackson Laboratory (Bar Harbor, ME). Forty  $\mu$ g of  
purified E. coli-derived recombinant human TNF (rhTNF) emulsified  
with an equal volume of complete Freund's adjuvant (obtained from



Difco Laboratories) in 0.4 ml was injected subcutaneously and intraperitoneally (i.p.) into a mouse. One week later, an injection of 5 µg of rHTNF in incomplete Freund's adjuvant was given i.p. followed by four consecutive i.p. injections of 10 µg of TNF without adjuvant. Eight weeks after the last injection, the mouse was boosted i.p. with 10 µg of TNF.

Four days later, the mouse was sacrificed, the spleen was obtained and a spleen cell suspension was prepared. Spleen cells were fused with cells of the nonsecreting hybridoma, Sp2/0 (ATCC CRL1581), at a 4:1 ratio of spleen cells to Sp2/0 cells, in the presence of 0.3 ml of 30% polyethylene glycol, PEG 1450. After incubation at 37°C for 6 hours, the fused cells were distributed in 0.2 ml aliquots into 96-well plates at concentrations of  $2 \times 10^4$  SP2/0 cells per well. Feeder cells, in the form of  $5 \times 10^4$  normal BALB/c spleen cells, were added to each well.

The growth medium used consisted of RPMI-1640 medium, 10% heat-inactivated fetal bovine serum (FBS) (Hyclone), 0.1 mM MEM nonessential amino acids, 1 mM sodium pyruvate, 2mM L-glutamine, 100 U/ml penicillin, 100 µg/ml streptomycin (GIBCO Laboratories) and, for selection, hypoxanthine-aminopterin-thymidine (HAT) (Boehringer Mannheim).

A solid-phase radioimmunoassay (RIA) was employed for screening supernatants for the presence of mAbs specific for rHTNFα. This assay is described in Example II, below. The background binding in this assay was about 500 cpm. A

supernatant was considered positive if it yielded binding of 2000 cpm or higher.

Of 322 supernatants screened, 25 were positive by RIA. Of these 25, the one with the highest binding (4800 cpm) was designated A2. Positive wells were subcloned at limiting dilution on mouse feeder cells. Upon further analysis of the supernatants in neutralization assays, A2 was found to be the only positive clone showing potent neutralizing activity. Thus, the hybridoma line A2 was selected. This line was maintained in RPMI-1640 medium with 10% FBS (GIBCO), 0.1 mM nonessential amino acids, 1 mM sodium pyruvate, 2 mM L-glutamine, 100 U/ml penicillin and 100 µg/ml streptomycin.

#### EXAMPLE II

##### Characterization of mAb A2

#### 15 A. Radioimmunoassays

E. coli-derived rhTNF was diluted to 1 µg/ml in BCB buffer, pH 9.6, and 0.1 ml of the solution was added to each assay well. After incubation at 4°C overnight, the wells were washed briefly with BCB, then sealed with 1% bovine serum albumin (BSA) in BCB at 37°C for 1 hr. The wells were then washed 3 times with PBS containing 0.05% Tween-20 (PBS-Tween), and 70 µl diluted A2 ascites fluid was added to each well. The wells were incubated for 2 hr at 37°C, and washed 3 times with PBS-Tween. Thereafter, approximately 50,000 cpm of <sup>125</sup>I-labeled F(ab')<sub>2</sub>

fragment of sheep anti-mouse Ig antibodies in 50  $\mu$ l of PBS-Tween containing 1% BSA was added to each well, and the wells were incubated for an additional 2 hr at 37°C. The wells were washed 4 times with PBS-Tween, cut out and counted individually.

5 Results of two determinations are shown in Figure 1.

rhTNF at 5  $\mu$ g/ml in PBS was heated to 60°C. At various time points, aliquots of the heat-treated TNF preparation were quickly cooled to 4°C, diluted 5-fold in BCB, and used to coat the RIA microplate wells. The RIA was carried out exactly as described above. Results from two determinations are shown in Figure 2. As incubation at 60°C substantially reduced the biological activity of hTNF $\alpha$ , this experiment shows MAb A2 fails to bind heat-inactivated human TNF $\alpha$ .

### 2. Neutralization Assays

15 Samples of A2 and cA2 were purified by protein A affinity chromatography from hybridoma tissue culture supernatants of cell lines designated C134A and C168A (described above), respectively, and diafiltered in phosphate buffered saline pH 7.2 (PBS).

20 The toxic effect of TNF on certain tumor cell lines has been adapted as an in vitro measure of TNF levels in laboratory samples and biological fluids. The assay method of Feinman et al., J. Immunol. 138:635-640 (1987), as modified by Aderka et al., J. Immunol. 141:3517-3523 (1989), employing the TNF-sensitive target cell A673 (a human rhabdomyosarcoma cell line), was used to investigate the ability of A2 to neutralize TNF toxicity.

Cultured human A673/6 cells were incubated with 40 pg/ml of natural (Genzyme, Boston, MA) or recombinant (Suntory, Osaka, Japan) human TNFs with varying concentrations of mAb A2 in the presence of 20 µg/ml cycloheximide at 39°C overnight.

5 Controls included medium alone or medium + TNF in each well. Cell death was measured by staining with naphthol blue-black, and the results read spectrophotometrically at 630 nm. Absorbance at this wave length correlates with the number of live cells present.

10 It was found that A2 neutralized the cytotoxic effect of both natural and rhTNF in a dose-dependent manner (Figure 3).

In another experiment, the specificity of this neutralizing activity was tested. A673/6 cells were seeded at  $3 \times 10^4$  cells/well 20 hr before the TNF bioassay. Two-fold serial  
15 dilutions of rhTNF, E. coli-derived recombinant human lymphotoxin (TNFβ), and E. coli-derived recombinant murine TNF were prepared. The A2 hybridoma supernatant was added to an equal volume of the diluted TNF preparations, and the mixtures were incubated at room temperature for 30 min. Aliquots of 0.1 ml were transferred to  
20 the wells containing A673/6 cells; 20 µg/ml of cycloheximide was added, and the cells were incubated at 39°C overnight. The cells were then fixed and stained for evaluation of cytotoxicity. The results indicate that mAb A2 specifically neutralized the cytotoxicity of rhTNFα, whereas it had no effect on human  
25 lymphotoxin (TNFβ) (Figure 4) or murine TNF (Figure 5).

Experiments were next performed to analyze the cross-reactivity of mAb A2 with TNF derived from non-human primates. Monocytes isolated from B514 (baboon), J91 (cynomolgus) and RH383 (rhesus) blood by Ficoll gradient centrifugation and adherence, were incubated at  $1 \times 10^5$  cells/well in RPMI 1640 medium with 5% FBS and 2  $\mu\text{g}/\text{ml}$  of *E. coli* LPS for 3 or 16 hr at 37°C to induce TNF production. Supernatants from duplicate wells were pooled and stored at 4°C for less than 20 hr until the TNF bioassay was performed, as described above, using A673/6 cells. Two-fold dilutions of the culture supernatants were mixed with either medium or purified mAb A2 at a final concentration of 1  $\mu\text{g}/\text{ml}$ , incubated at room temperature for 30 min and aliquots transferred to the indicator cells. The results showed that mAb A2 failed to significantly neutralize the cytotoxic activity of TNF produced by baboon, cynomolgus and rhesus monkey monocytes.

A further experiment was conducted with chimpanzee TNF. Monocytes isolated from CH563 (chimpanzee) blood were incubated as described above to generate TNF-containing supernatants. The ability of 10  $\mu\text{g}/\text{ml}$  of mAb A2 to neutralize the bioactivity of these supernatants was assayed as above. Human TNF was used as a positive control. Results, shown in Figure 6, indicate that mAb A2 had potent neutralizing activity for chimpanzee TNF, similar to that for human TNF (Figure 7).

The neutralizing activity of mAb A2 was compared with three other murine mAbs specific for human TNF, termed TNF-1, TNF-2 and TNF-3, and a control mAb. Two-fold serial dilutions

of purified mAbs were mixed with rhTNF (40 pg/ml), incubated at room temperature for 30 min, and aliquots tested for TNF bioactivity as above. It was found that mAbs TNF-1, TNF-2 and TNF-3 each had a similar moderate degree of neutralizing activity. In contrast, mAb A2 had much more potent neutralizing activity.

### EXAMPLE III

#### General Strategy for Cloning Antibody V and C Genes

The strategy for cloning the V regions for the H and L chain genes from the hybridoma A2, which secretes the anti-TNF antibody described above, was based upon the linkage in the genome between the V region and the corresponding J (joining) region for functionally rearranged (and expressed) Ig genes. J region DNA probes can be used to screen genomic libraries to isolate DNA linked to the J regions. Although DNA in the germline configuration (i.e., unrearranged) would also hybridize to J probes, this DNA would not be linked to a Ig V region sequence and can be identified by restriction enzyme analysis of the isolated clones.

The cloning utilized herein was to isolate V regions from rearranged H and L chain genes using  $J_H$  and  $J_L$  probes. These clones were tested to see if their sequences were expressed in the A2 hybridoma by Northern analysis. Those clones that contained expressed sequence were cloned into

expression vectors containing human C regions and transfected into mouse myeloma cells to determine if an antibody was produced. The antibody from producing cells was then tested for binding specificity and functionally compared to the A2 murine antibody.

#### EXAMPLE IV

##### Construction of a L Chain Genomic Library

To isolate the L chain V region gene from the A2 hybridoma, a size-selected genomic library was constructed using the phage lambda vector charon 27. High molecular weight DNA was isolated from A2 hybridoma cells and digested to completion with restriction endonuclease HindIII. The DNA was then fractionated on a 0.8% agarose gel and the DNA fragments of three different size ranges of approximately 3 kb, 4 kb and 6 kb were isolated from the gel by electroelution. The size ranges for library construction were chosen based upon the size of HindIII fragments that hybridized on a southern blot with the J<sub>κ</sub> probe. After phenol/chloroform extraction and ethanol precipitation, the DNA fragments from each size class were ligated with lambda charon 27 arms and packaged into phage particles in vitro using Gigapack Gold from Stratagene (LaJolla, CA).

These libraries were screened directly at a density of approximately 20,000 plaques per 150 mm petri dish using a <sup>32</sup>P-labeled J<sub>κ</sub> probe. The mouse L chain J<sub>κ</sub> probe was a 2.7 kb HindIII fragment containing all five J<sub>κ</sub> segments. The probe was

labeled with  $^{32}\text{P}$  by random priming using a kit obtained from Boehringer Mannheim. Free nucleotides were removed by centrifugation through a Sephadex G-50 column. The specific activities of the probe was approximately  $10^9$  cpm/ $\mu\text{g}$ .

5           Plaque hybridizations were carried out in 5x SSC, 50% formamide, 2x Denhardt's reagent, and 200  $\mu\text{g}/\text{ml}$  denatured salmon sperm DNA at 42°C for 18-20 hours. Final washes were in 0.5x SSC, 0.1% SDS at 65°C. Positive clones were identified after autoradiography.

#### 10                           EXAMPLE V

##### Construction of H Chain Genomic Library

To isolate the V region gene for the A2 H chain, a genomic library was constructed in the lambda gt10 vector system. High molecular weight DNA was digested to completion with  
15 restriction endonuclease EcoRI and fragments of approximately 7.5 kb were isolated after agarose gel electrophoresis. These fragments were ligated with lambda gt10 arms and packaged into phage particles in vitro using Gigapack Gold.

This library was screened at a density of 20,000  
20 plaques per 150 mm plate using a  $J_H$  probe. The  $J_H$  probe was a 2kb BamHI/EcoRI fragment containing both  $J_3$  and  $J_4$  segments. The probe was labeled as in Example III and had a similar specific radioactivity. Hybridization and wash conditions were identical to those used in Example III.



EXAMPLE VI

Cloning of the TNF-Specific V gene regions

Several positive clones were isolated from the H and L chain libraries after screening approximately  $10^6$  plaques from each library using the  $J_H$  and  $J_K$  probes, respectively. Following plaque purification, bacteriophage DNA was isolated for each positive clone, digested with either EcoRI (H chain clones) or HindIII (L chain clones) and fractionated on 1% agarose gels. The DNA was transferred to nitrocellulose and the blots were hybridized with the  $J_H$  or the  $J_K$  probe.

Several H chain clones were obtained that contained 7.5 kb EcoRI DNA fragments that hybridized to the  $J_H$  probe. For the light chain libraries, several clones from each of the three size-selected libraries were isolated that contained HindIII fragments that hybridize to the  $J_K$  probe. For the L chain, several independently derived HindIII fragments of 2.9 kb from the 2 kb library hybridized with a 1250 bp mRNA from A2, but not with SP2/0 mRNA (see Example VII). In addition, several HindIII fragments derived from the 4 kb library hybridized both to the A2 mRNA and the fusion partner mRNA. A 5.7 kb HindIII fragment from the 6 kb library did not hybridize to either RNA.

The observed lengths of hybridizing A2 mRNA were the correct sizes for H and L chain mRNA, respectively. Because the RNA expression was restricted to the A2 hybridoma, it was assumed that the 7.5 kb H chain fragments and the 2.9 kb L chain

fragments contained the correct V region sequences from A2. One example of each type was chosen for further study. The important functional test is the demonstration that these V regions sequences, when combined with appropriate C region sequences, are  
5 capable of directing the synthesis of an antibody with a specificity and affinity similar to that of the murine A2 antibody.

The 7.5 kb H chain fragment and the 2.9 kb L chain fragment were subcloned into plasmid vectors that allow  
10 expression of the chimeric mouse/human proteins in murine myeloma cells (see Examples VIII and IX). These plasmids were cotransfected into SP2/0 cells to ascertain if intact antibody molecules were secreted, and if so, if they were of the correct specificity and affinity. Control transfections were also  
15 performed pairing the putative anti-TNF H chain with an irrelevant, but expressed, L chain; the putative anti-TNF L chain was also paired with an irrelevant, but expressed, H chain. The results indicated that the 7.5 kb H chain fragment could be expressed, whereas the 2.9 kb L chain fragment could not. This  
20 was confirmed by DNA sequence analysis that suggested portions of the coding region were not in the proper amino acid reading frame when compared to other known L chain amino acid sequences.

Because the 2.9 kb HindIII fragment appeared not to contain a functional V gene, the 4.0 kb and 5.7 kb HindIII  
25 fragments isolated from L chain libraries were cloned into expression vectors and tested for expression of chimeric antibody

41300012

after cotransfection with the 7.5 kb H chain. The 5.7 kb HindIII fragment was incapable of supporting antibody expression, whereas the 4.0 kb HindIII fragment did support antibody expression. The antibody resulting from the cotransfection of the 7.5 kb putative  
5 H chain V region and the 4.0 kb L chain V region was purified, tested in solid phase TNF binding assay, and found to be inactive. It was concluded that the V region contained on the 4.0 kb HindIII fragment was not the correct anti-TNF V regions, but was contributed to the hybridoma by the fusion partner. This  
10 was subsequently confirmed by sequence analysis of cDNA derived from the A2 hybridoma and from the fusion partner.

Other independently derived L chain clones containing 2.9 kb HindIII fragments that hybridized with A2 mRNA were characterized in more detail. Although the restriction maps were  
15 similar, the clones fell into two classes with respect to the presence or absence of an AccI enzyme site. The original (non-functional) 2.9 kb fragment (designated clone 8.3) was missing an AccI site present in some other clones (represented by clone 4.3). The DNA sequence of clone 4.3 was extremely similar to  
20 clone 8.3, but contained a single amino acid reading frame with close homology to known L chains, unlike clone 8.3. The 2.9 kb HindIII fragment from clone 4.3 was subcloned into the L chain expression vector and cotransfected with the putative anti-TNF H chain into SP2/0 cells. An antibody was synthesized, purified  
25 and tested in the solid phase TNF binding assay. This antibody

bound to TNF, and therefore, the clone 4.3 L chain V region was assumed to be the correct one.

The A2 murine hybridoma has been shown to contain at least four rearranged L chain V region genes. At least two of these are expressed as proteins: clone 4.3 (the correct anti-TNF L chain gene) and the gene contained in the 4.0 kb HindIII fragment (contributed by the fusion partner). The expression of two L chains implies that the resulting antibody secreted from the murine hybridoma is actually a mixture of antibodies, some using the correct L chain, some using the incorrect L chain, and some using one of each. The presence of two different L chains in the murine A2 antibody has been confirmed by SDS gel and N-terminal protein sequence analysis of the purified antibody. Because construction of the chimeric A2 antibody involves cloning the individual H and L chain genes and expressing them in a non-producing cell line, the resulting antibody will have only the correct L chain and therefore should be a more potent antibody (see Examples X, XI and XII).

#### EXAMPLE VII

##### Northern Analysis of Cloned DNA

Cloned DNA corresponding to the authentic H and L chain V regions from the A2 hybridoma would be expected to hybridize to A2 mRNA. Non-functional DNA rearrangements at either the H or L chain genetic loci should not be expressed.

4 10 00 02

Ten µg total cellular RNA was subjected to electrophoresis on 1% agarose/formaldehyde gels (Sambrook et al., supra) and transferred to nitrocellulose. Blots were hybridized with random primed DNA probes in 50% formamide, 2x Denhardt's solution, 5x SSC, and 200 µg/ml denatured salmon sperm DNA at 42°C for 10 hours. Final wash conditions were 0.5 x SSC, 0.1% SDS at 65°C.

The subcloned DNA fragments were labeled with <sup>32</sup>P by random priming and hybridized to Northern blots containing total RNA derived from A2 cells or from cells of SP2/0, the fusion partner parent of A2. The 7.5 kb EcoRI H chain fragment hybridized with a 2 kb mRNA from A2, but not with SP2/0 mRNA. Similarly, the 2.9 kb L chain HindIII fragment (clone 4.3) hybridized with a 1250 bp mRNA from A2, but not with SP2/0 mRNA.

15 The observed lengths of A2 mRNA hybridizing were the correct sizes for H and L chain mRNA, respectively, confirming that the V region sequences on these DNA fragments are expressed in A2 hybridoma cells.

#### EXAMPLE VIII

##### 20 Construction of Expression Vectors

The putative L (clone 4.3) and H chain V genes described above were joined to human kappa and gamma constant region genes in expression vectors. The 7.5 kb EcoRI fragment corresponding to the putative V<sub>H</sub> region gene from A2 was cloned

into an expression vector containing the human C<sub>γ</sub> gene and the Eco<sub>g</sub>pt gene to yield the plasmid designated pA2HG1ap<sub>g</sub>pt (see Figure 8).

5 The 2.9 kb putative V<sub>L</sub> fragment from clone 4.3 was cloned into a vector containing the human kappa C<sub>κ</sub> gene and the Eco<sub>g</sub>pt gene to allow selection in mammalian cells. The resulting plasmid was designated pA2HuKap<sub>g</sub>pt (See Figure 8).

#### EXAMPLE IX

##### Expression of Chimeric Antibody Genes

10 To express the chimeric H and L chain genes, the expression plasmids were transfected into cells of the non-producing mouse myeloma cell line, SP2/0. Plasmid DNA to be transfected was purified by centrifuging to equilibrium in ethidium bromide/cesium chloride gradients twice. Plasmid DNA  
15 (10-50 μg) was added to 10<sup>7</sup> SP2/0 cells in medium containing Hank's salts, and the mixture was placed in a BioRad electroporation apparatus. Electroporation was performed at 20 volts, following which the cells were plated in 96 well microtiter plates.

20 Mycophenolic acid selection was applied after 24 hours and drug resistant colonies were identified after 1-2 weeks. Resistant colonies were expanded to stable cell lines and tissue culture supernatant from these cell lines was tested for antibody using an ELISA assay with goat anti-human IgG Fc antibody and

goat anti-human H+L conjugated with alkaline phosphatase  
(obtained from Jackson Laboratories).

The chimeric A2 antibody was purified from tissue  
culture supernatant by Protein A- Sepharose chromatography. The  
5 supernatant was adjusted to 0.1M Tris, 0.002M EDTA, pH 8.0 and  
loaded on a Protein A-Sepharose column equilibrated in the same  
buffer. The IgG was eluted with 0.1M citrate, pH 3.5,  
neutralized with 1M Tris, and dialyzed into phosphate-buffered  
saline (PBS).

10 The purified chimeric antibody was evaluated for its  
binding and neutralizing activity.

#### EXAMPLE X

##### Specificity of Chimeric A2 Antibody

Since the antigen binding domain of cA2 was derived  
15 from murine A2, these mAbs would be expected to compete for the  
same binding site on TNF. Fixed concentrations of chimeric A2  
and murine mAb A2 were incubated with increasing concentrations  
of murine and chimeric A2 competitor, respectively, in a 96-well  
microtiter plate coated with rhTNF (Dainippon, Osaka, Japan).  
20 Alkaline-phosphatase conjugated anti-human immunoglobulin and  
anti-mouse immunoglobulin second antibodies were used to detect  
the level of binding of chimeric and murine A2, respectively.  
Cross-competition for TNF antigen was observed in this solid-

phase ELISA format (Figure 9). This finding is consistent with the expected identical epitope specificity of CA2 and murine A2.

The affinity constant for binding of mouse mAb A2 and CA2 to rhTNF $\alpha$  was determined by Scatchard analysis (see, for example, Scatchard, G., Ann. N.Y. Acad. Sci. 51:660 (1949)). The results are shown in Figure 10. This analysis involved measuring the direct binding of  $^{125}\text{I}$  labelled CA2 to immobilized rhTNF $\alpha$  in a 96-well plate. The antibodies were each labelled to a specific activity of about 9.7  $\mu\text{Ci}/\mu\text{g}$  by the iodogen method. An affinity constant ( $K_a$ ) of  $0.5 \times 10^9$  liters/mole was calculated for the mouse mAb A2. Unexpectedly, the chimeric A2 antibody had a higher affinity, with a  $K_a$  of  $1.8 \times 10^9$  liters/mole. Thus, the chimeric anti-TNF $\alpha$  antibody of the present invention was shown to exhibit a significantly higher affinity of binding to human TNF $\alpha$  than did the parental murine A2 mAb. This finding was surprising, since chimeric antibodies would be expected to have affinities that are equal to or less than that of the parent mAb.

Such high affinity anti-TNF antibodies, having affinities of binding to TNF $\alpha$  of at least  $1 \times 10^8 \text{ M}^{-1}$ , more preferably at least  $1 \times 10^9 \text{ M}^{-1}$  (expressed as  $K_a$ ) are preferred for immunoassays which detect very low levels of TNF in biological fluids. In addition, anti-TNF antibodies having such high affinities are preferred for therapy of TNF- $\alpha$ -mediated conditions or disease states.



The specificity of cA2 for TNF was confirmed by testing for cross-neutralization of human lymphotoxin (TNF- $\beta$ ).

Lymphotoxin shares some sequence homology and certain biological activities, for example, tumor cell cytotoxicity, with TNF

5 (Pennica, D. et al., Nature 312:724-729 (1984)). Cultured human A673 cells were incubated with increasing concentrations of human lymphotoxin (Genentech, San Francisco, CA) with or without 4  $\mu$ g/ml chimeric A2 in the presence of 20  $\mu$ g/ml cycloheximide at 39°C overnight. Cell death was measured by vital staining with  
10 naphthol blue-black, as above. The results indicated that cA2 was ineffective at neutralizing human lymphotoxin, confirming the TNF $\alpha$ -specificity of the chimeric antibody.

The ability of A2 or cA2 to react with TNF from different animal species was also evaluated. As mentioned  
15 earlier, there are multiple epitopes on human TNF to which neutralizing mAbs will bind (Moller, A. et al., supra). Human TNF has bioactivity in a wide range of host animal species. However, certain neutralizing epitopes on human TNF are conserved amongst different animal species and others appear to be  
20 restricted to humans and chimpanzees.

Neutralization experiments utilized endotoxin-activated cell supernatants from freshly isolated human, chimpanzee, rhesus and cynomolgus monkey, baboon, pig, dog, rabbit, or rat monocytes as the TNF source. As discussed above, murine mAb A2 neutralized  
25 activity of only human and chimpanzee TNF, and had no effect on TNF derived from other primates and lower animals. A2 also did

not neutralize the cytotoxic effect of recombinant mouse TNF. Thus, the epitope recognized by A2 is one shared by human and chimpanzee TNF $\alpha$ . Chimeric A2 was also tested in this manner for cross-reactivity with monocyte-derived TNF from rat, rabbit, dog  
5 and pig, as well as with purified recombinant mouse TNF $\alpha$ , and natural and recombinant human TNF $\alpha$ . Chimeric A2 only neutralized natural and recombinant human TNF $\alpha$ . Therefore, cA2 appears to share species specificity with murine A2.

#### EXAMPLE XI

##### 10 In Vitro Activity and Neutralization Efficacy of cA2 Antibody

Both the murine and chimeric anti-TNF $\alpha$  antibodies, A2 and cA2 have potent TNF-neutralizing activity. In the TNF cytotoxicity assay described above, murine A2, at a concentration of about 125 ng/ml completely neutralized the biological activity  
15 of a 40 pg/ml challenge of rhTNF $\alpha$ . Two separate determinations of neutralizing potency, expressed as the 50% Inhibitory Dose (ID50) were determined to be  $15.9 \pm 1.01$  and  $17.9 \pm 1.6$  ng/ml (Mean  $\pm$  Std error). Thus the mAb A2 has an ID50 of about 17 ng/ml.

20 In this same experimental system, three other murine anti-TNF $\alpha$  antibodies (termed TNF-1, TNF-2 and TNF-3) of comparable binding affinity to TNF were found to have ID50 values of 1-2 orders of magnitude greater, and thus were significantly less potent in neutralization than A2.

The ability of cA2 to neutralize human TNF $\alpha$  bioactivity in vitro was tested using the bioassay system described above. Cultured A673 cells were incubated with 40 pg/ml natural (Genzyme, Boston, MA) or recombinant (Suntory, Osaka, Japan) human TNF with or without antibody overnight as above, and cell death was measured by vital staining. As expected based upon the above results with the A2 mouse mAb, cA2 also neutralized both natural and rhTNF in a dose-dependent manner in the cytotoxicity assay (Figure 11). In this assay format, levels of cA2 as low as 125 ng/ml completely abolished the toxic activity of TNF. Upon repeated analysis, the cA2 exhibited greater TNF-neutralizing activity than did the parent murine A2 mAb. Such neutralizing potency, at antibody levels below 1  $\mu$ g/ml, can easily be attained in the blood of a subject to whom the antibody is administered. Accordingly, such highly potent neutralizing anti-TNF antibodies, in particular the chimeric antibody, are preferred for therapeutic use in TNF $\alpha$ -mediated diseases or conditions.

As mentioned above, TNF induces cellular secretion of IL-6. Furthermore, there is evidence that IL-6 is involved in the pathophysiology of sepsis, although the precise role of IL-6 in that syndrome is unclear (Fong, Y. *et al.*, *J Exp Med* 170:1627-1633 (1989); Starnes Jr., H.F. *et al.*, *J Immunol* 145:4185-4191 (1990)). The ability of cA2 to neutralize TNF-induced IL-6 secretion was evaluated using cultured human diploid FS-4 fibroblasts. The results in Table 1 show that cA2 was effective in blocking IL-6 secretion in cells that had been incubated

overnight with TNF. TNF-induced IL-6 secretion was not inhibited in the absence of a mAb or in the presence of a control mAb specific for an irrelevant antigen.

5

TABLE 1

IN VITRO NEUTRALIZATION OF TNF-INDUCED IL-6 SECRETION

| <u>Antibody</u> | <u>TNF Concentration (ng/ml)</u> |            |            |            |
|-----------------|----------------------------------|------------|------------|------------|
|                 | <u>0</u>                         | <u>0.3</u> | <u>1.5</u> | <u>7.5</u> |
| None            | <0.20                            | 1.36       | 2.00       | 2.56       |
| 10 Control mAb  | <0.20                            | 1.60       | 1.96       | 2.16       |
| cA2             | <0.20                            | <0.20      | <0.20      | 0.30       |

15 Values represent mean concentrations of IL-6 of duplicate wells, in ng/ml. RhTNF (Suntory, Osaka, Japan), with or without 4 µg/ml antibody, was added to cultures of FS-4 fibroblasts and after 18 h, the supernatant was assayed for IL-6 using the Quantikine Human IL-6 Immunoassay (from R&D Systems, Minneapolis, MN). Control mAb = chimeric mouse/human IgG1 anti-platelet mAb (7E3).

20

The ability of TNF to activate procoagulant and adhesion molecule activities of endothelial cells (EC) is thought to be an important component of disease pathophysiology. In particular, this may be associated with the vascular damage, disseminated intravascular coagulation, and severe hypotension that is associated with the sepsis syndrome. Therefore, the ability of cA2 to block TNF-induced activation of cultured human umbilical vein endothelial cells (HUVEC) was evaluated. TNF stimulation of procoagulant activity was determined by exposing intact cultured HUVEC cells to TNF (with or without antibody) for

4 hours and analyzing a cell lysate in a human plasma clotting assay. The results in Table 2 show the expected upregulation by TNF of HUVEC procoagulant activity (reflected by a decreased clotting time). Chimeric antibody cA2 effectively neutralized this TNF activity in a dose-dependent manner.

TABLE 2

IN VITRO NEUTRALIZATION OF TNF-INDUCED PROCOAGULANT ACTIVITY

|    | Antibody   | $\mu\text{g/ml}$ | TNF Concentration (ng/ml) |              |              |
|----|------------|------------------|---------------------------|--------------|--------------|
|    |            |                  | 250                       | 25           | 0            |
| 10 | None       | -                | $64 \pm 4^*$              | $63 \pm 1$   | $133 \pm 13$ |
|    | Control Ab | 10.00            | $74 \pm 6$                | N.D.         | $178 \pm 55$ |
|    | cA2        | 10.00            | $114 \pm 5$               | $185 \pm 61$ | $141 \pm 18$ |
| 15 | cA2        | 3.30             | $113 \pm 2$               | $147 \pm 3$  | N.D.         |
|    | cA2        | 1.10             | $106 \pm 1$               | $145 \pm 8$  | N.D.         |
|    | cA2        | 0.37             | $73 \pm 17$               | $153 \pm 4$  | N.D.         |
|    | cA2        | 0.12             | $64 \pm 1$                | $118 \pm 13$ | N.D.         |

\* Values represent mean plasma clotting time, in seconds ( $\pm$  S.D.). Clotting time was determined in normal human plasma after addition of the rhTNF (Dainippon, Osaka, Japan) with or without antibody-treated HUVEC lysate and  $\text{Ca}^{++}$  at  $37^\circ\text{C}$ . N.D. = Not done. Control Ab is a chimeric mouse/human IgG1 anti-CD4 antibody.

In addition to stimulating procoagulant activity, TNF also induces surface expression of endothelial cell adhesion molecules such as ELAM-1 and ICAM-1. The ability of cA2 to neutralize this activity of TNF was measured using an ELAM-1 specific detection radioimmunoassay. Cultured HUVEC were

stimulated with 250 ng/ml rhTNF (Dainippon, Osaka, Japan) with or without antibody at 37°C overnight in a 96-well plate format. Surface expression of ELAM-1 was determined by sequential addition of a mouse anti-human ELAM-1 mAb and <sup>125</sup>I-labelled rabbit anti-mouse immunoglobulin second antibody directly to culture plates at 4°C.

As shown in Figure 12, TNF induced the expression of ELAM-1 on the surface of cultured HUVEC cells, and this activity was again effectively blocked in a dose-related manner by cA2.

Finally, TNF is known to stimulate mitogenic activity in cultured fibroblasts. Chimeric A2 neutralized TNF-induced mitogenesis of human diploid FS-4 fibroblasts cultures, confirming the potent neutralizing capability of cA2 against a broad spectrum of in vitro TNF biological activities.

#### EXAMPLE XII

##### In Vivo Activity and Efficacy of cA2 Antibody

The highly restrictive species cross-reactivity of cA2 severely limits the ability to test the in vivo efficacy of this antibody in animals other than humans or chimpanzees.

Nevertheless, evidence that the potent in vitro neutralizing capability of cA2 is manifest in vivo was desirable. Earlier animal studies showed that administration of TNF to experimental

animals mimics the disease state obtained with either Gram-negative bacterial infection or direct endotoxin administration (Tracey, K.J. et al., 1986. supra; Tracey, K.J. et al., 1987, supra; Lehmann, V. et al., supra).

5        An in vivo model wherein lethal doses of human TNF are administered to galactosamine-sensitized mice (Lehmann, V. et al., supra) was adapted for testing the capability of cA2 to neutralize TNF in vivo. An i.p. challenge with 5  $\mu$ g (0.25 mg/kg) of rhTNF resulted in 80-90 percent mortality in untreated  
10 control animals and in animals treated i.v. 15-30 minutes later with either saline or 2 mg/kg control antibody (a chimeric IgG1 derived from murine 7E3 anti-platelet mAb). In contrast, treatment with cA2 reduced mortality to 0-30 percent with 0.4 mg/kg of antibody, and to 0-10 percent with 20 mg/kgs. These  
15 results, summarized in Table 4, indicate that cA2 was capable of

neutralizing the biological activity of TNF in vivo as well as in vitro.

TABLE 4

PREVENTION OF HUMAN TNF-INDUCED LETHALITY BY CHIMERIC A2

Outcome (Survivors/Total)

| Antibody            | Experiment #1   | Experiment #2    |
|---------------------|-----------------|------------------|
| None                | 1/10            | N.D.             |
| Control Ab, 2 mg/kg | 2/10            | 1/10             |
| 10 cA2 (2 mg/kg)    | 9/10 (p=0.0055) | 10/10 (p=0.0001) |
| cA2 (0.4 mg/kg)     | 7/10 (p=0.07)   | 10/10 (p=0.0001) |

Female C3H/HeN mice were administered 5 µg rHTNF (Dainippon, Osaka, Japan) + 18 mg galactosamine i.p. and antibody was administered 15-30 minutes later i.v. Deaths were recorded 48 h post-challenge. Control MAb = chimeric mouse/human IgG1 anti-platelet MAb (7E3). N.D. = not done. p values refer to comparison with the control Ab.

The references cited above are all incorporated by reference herein, whether specifically incorporated or not.

Having now fully described this invention, it will be appreciated by those skilled in the art that the same can be performed within a wide range of equivalent parameters, concentrations, and conditions without departing from the spirit and scope of the invention and without undue experimentation.

While this invention has been described in connection with specific embodiments thereof, it will be understood that it



is capable of further modifications. This application is intended to cover any variations, uses, or adaptations of the inventions following, in general, the principles of the invention and including such departures from the present disclosure as come  
5 within known or customary practice within the art to which the invention pertains and as may be applied to the essential features hereinbefore set forth as follows in the scope of the appended claims. It is to be understood that the phraseology or terminology employed herein is for the purpose of description and  
10 not of limitation.

WHAT IS CLAIMED IS:

1. A high-affinity mouse monoclonal antibody to human tumor necrosis factor- $\alpha$  (TNF $\alpha$ ) designated A2 which binds to a neutralizing epitope of human TNF $\alpha$ .
- 5           2. A mouse monoclonal antibody according to claim 1 in detectably labeled form.
3. A chimeric immunoglobulin chain comprising at least part of a human immunoglobulin constant region and at least part of a non-human immunoglobulin variable region having  
10   specificity to human TNF $\alpha$ .
4. A chimeric immunoglobulin chain according to claim 3 which is a heavy chain.
5. A chimeric immunoglobulin chain according to claim 3 which is a light chain.
- 15           6. A chimeric antibody molecule comprising two light chains and two heavy chains, each of said chains comprising at least part of a human constant region and at least part of a variable region having specificity to human TNF $\alpha$ , said antibody binding with high affinity to a neutralizing epitope of human  
20   TNF $\alpha$ .

7. A chimeric antibody according to claim 6 which does not bind to TNF $\beta$ .

8. A chimeric antibody according to claim 6, wherein said variable region is of murine origin.

5 9. A chimeric antibody according to claim 8, wherein said variable region is derived from a high affinity murine monoclonal antibody which binds to a neutralizing epitope of human TNF $\alpha$ .

10 10. A chimeric antibody according to claim 9, wherein said murine monoclonal antibody is A2 or a monoclonal antibody which competitively inhibits the binding of A2 to TNF $\alpha$ .

11. A chimeric antibody according to claim 9, wherein said murine monoclonal antibody is A2.

15 12. A chimeric antibody according to claim 6 wherein said affinity, measured as an association constant ( $K_a$ ), is at least  $1 \times 10^8$  liter/mole.

13. A chimeric antibody according to claim 6 wherein said affinity, measured as an association constant ( $K_a$ ), is at least  $1 \times 10^9$  liter/mole.

14. A chimeric antibody according to claim 6 which neutralizes human TNF $\alpha$  with an ID50 of at least about 1  $\mu$ g/ml.

15. A chimeric antibody according to claim 6 which neutralizes human TNF $\alpha$  with an ID50 of at least about 100 ng/ml.

5 16. A chimeric antibody according to claim 6 which neutralizes human TNF $\alpha$  with an ID50 of at least about 15 ng/ml.

17. A chimeric antibody according to claim 6 in detectably labeled form.

18. A polynucleotide molecule comprising:

- 10 (a) a first nucleotide sequence encoding at least a part of the variable region of an immunoglobulin chain having specificity to human TNF $\alpha$ ; and
- (b) an second nucleotide sequence encoding at least a part of the constant region of a human
- 15 immunoglobulin chain,

both said sequences in operable linkage with each other, wherein said sequences are not in operable linkage with each other in nature, wherein said polynucleotide molecule encodes a protein chain capable of yielding an antibody with high affinity binding

20 to said human TNF $\alpha$ .

19. A molecule according to claim 18 wherein said first nucleotide sequence is a genomic DNA sequence.

20. A molecule according to claim 18 wherein said first nucleotide sequence is a cDNA sequence.

5 21. A molecule according to claim 18 wherein said second nucleotide sequence is a cDNA sequence.

22. A molecule according to claim 18 wherein said variable region is of murine origin.

23. A molecule according to claim 22 wherein said  
10 variable region is derived from a murine monoclonal antibody.

24. A molecule according to claim 23 wherein said murine monoclonal antibody is A2.

25. A molecule according to claim 18 wherein said immunoglobulin chain is a heavy chain.

15 26. A molecule according to claim 18 wherein said immunoglobulin chain is a light chain.

27. A molecule according to claim 18 in double stranded DNA form.

28. A molecule according to claim 18 which is an expression vehicle.

29. A molecule according to claim 28 wherein said vehicle is a plasmid.

5 30. A host transformed or transfected with the molecule of claim 29.

31. A host according to claim 30 which is a eukaryotic cell.

32. A host according to claim 31 which is a mammalian  
10 cell.

33. A DNA molecule comprising a DNA sequence encoding a chimeric antibody molecule according to claim 6.

34. A process for preparing a chimeric antibody according to claim 6, comprising:

- (a) culturing a host capable of expressing said heavy chain and said light chain under culturing conditions,
- (b) expressing said chimeric antibody; and
- (c) recovering said chimeric antibody from said culture.

35. A method for treating a subject having a disease or condition mediated by TNF $\alpha$  comprising administering to said subject a therapeutic amount of a monoclonal antibody according to claim 1.

36. A method for treating a subject having a disease or condition mediated by TNF $\alpha$  comprising administering to said subject a therapeutic amount of a chimeric antibody according to claim 6.

4 13 00 12

37. A method of removing from a fluid TNF $\alpha$ , a fragment thereof, or an immune complex containing said TNF $\alpha$ , the method comprising:

- 5 (a) delivering said fluid to a device containing a monoclonal antibody according to claim 1 in immobilized form; and
  - (b) allowing binding of said TNF $\alpha$ , fragment or immune complex to said immobilized antibody,
- 10 thereby removing said TNF $\alpha$ , fragment or immune complex from said fluid.

38. A method of removing from a fluid TNF $\alpha$ , a fragment thereof, or an immune complex containing said TNF $\alpha$ , the method comprising:

- 15 (a) delivering said fluid to a device containing a chimeric antibody according to claim 6 in immobilized form; and
  - (b) allowing binding of said TNF $\alpha$ , fragment or immune complex to said immobilized antibody,
- 20 thereby removing said TNF $\alpha$ , fragment or immune complex from said fluid.



39. A method of treating a subject suspected of having a disease or condition associated with elevated levels of TNF $\alpha$  in a body fluid, comprising:

- (a) removing said TNF $\alpha$  from said body fluid using a method according to claim 38; and
- (b) returning said body fluid to said subject.

40. A method of treating a subject suspected of having a disease or condition associated with elevated levels of TNF $\alpha$  in a body fluid, comprising:

- (a) removing said TNF $\alpha$  from said body fluid using a method according to claim 38; and
- (b) returning said body fluid to said subject.

41. An immunoassay method for detecting human TNF $\alpha$  in a sample, comprising:

- (a) contacting said sample with a monoclonal antibody according to claim 1; and
- (b) detecting the binding of the antibody to said TNF $\alpha$ .

4180312

42. An immun assay method for detecting human TNF $\alpha$  in a sample, comprising:

- (a) contacting said sample with a chimeric antibody according to claim 6;
- (b) detecting the binding of the antibody to said antigen.

5

SL:VILCEK3.APP

- 86 -

031891



4100000

ABSTRACT OF THE DISCLOSURE

High affinity neutralizing monoclonal and chimeric antibodies specific for human tumor necrosis factor- $\alpha$  (TNF $\alpha$ ) are useful in diagnosis and therapy of a number of TNF $\alpha$ -mediated diseases and conditions, including sepsis syndrome, cachexia, circulatory collapse and shock resulting from acute or chronic bacterial infection, acute and chronic parasitic or infectious processes, including bacterial, viral and fungal infections, acute and chronic immune and autoimmune diseases, such as systemic lupus erythematosus and rheumatoid arthritis, alcohol-induced hepatitis, chronic inflammatory disease, vascular inflammatory diseases, graft-versus-host disease, Kawasaki's disease and malignant diseases. Polynucleotide molecules coding for the chimeric antibody, methods of producing the antibody, methods of use of the mouse monoclonal and chimeric antibody in immunoassays and immunotherapeutic approaches are provided.

MAIL ROOM  
MAY 20 1991

Atty's Docket:

Combined Declaration for Patent Application and Power of Attorney

I, the undersigned, being a lawful resident of the United States of America, hereby declare that:  
my residence, post office address and citizenship are as stated below next to my name:

I am the original, first and sole inventor (if only one name is listed below) or an original, first and joint inventor (if plural names are listed below) of the subject matter which is claimed and for which a patent is sought on the invention entitled  
Monoclonal and Chimeric Antibodies Specific for Human Tumor Necrosis Factor

(check one) ☐ is attached hereto.  
☒ was filed on March 18, 1991  
U.S. or PCT Application Serial No. Not yet assigned  
and was amended on \_\_\_\_\_  
(If applicable)

I hereby state that I have reviewed and understand the contents of the above identified specification, including the claims, as amended by any amendment referred to above.

I acknowledge the duty to disclose information which is material to the examination of this application in accordance with Title 37, Code of Federal Regulations, § 1.56(a).

I hereby claim foreign priority benefits under Title 35, United States Code, § 119 of any foreign application(s) for patent or inventor's certificate listed below and have also identified below any foreign application for patent or inventor's certificate having filing date before that of the application on which priority is claimed:

| Prior Foreign Application(s) |           |               | Priority Claimed              |                               |
|------------------------------|-----------|---------------|-------------------------------|-------------------------------|
| (Number)                     | (Country) | (Filing Date) | <input type="checkbox"/> 11.1 | <input type="checkbox"/> 11.2 |
| (Number)                     | (Country) | (Filing Date) | <input type="checkbox"/> 11.3 | <input type="checkbox"/> 11.4 |
| (Number)                     | (Country) | (Filing Date) | <input type="checkbox"/> 11.5 | <input type="checkbox"/> 11.6 |

I hereby claim the benefit under Title 35, United States Code, § 120 of any United States Application(s) listed below and, insofar as the subject matter of each of the claims of this application is not disclosed in the prior United States application in the manner provided by the first paragraph of Title 35, United States Code, § 112, I acknowledge the duty to disclose material information as defined in Title 37, Code of Federal Regulations, § 1.56(a) which occurred between the filing date of the prior application and the national or PCT international filing date of this application:

|                          |               |          |
|--------------------------|---------------|----------|
| (Application Serial No.) | (Filing Date) | (Status) |
| (Application Serial No.) | (Filing Date) | (Status) |
| (Application Serial No.) | (Filing Date) | (Status) |

I hereby appoint the following attorneys, with full power of substitution, association, and revocation, to prosecute this application and to transact all business in the Patent and Trademark Office connected therewith.

SHERIDAN NEIMARK, REG. NO. 20,320 - ROGER L. BACLOT, REG. NO. 25,418 - ALVIN H. ECKHART, REG. NO. 25,004  
JEROME J. MORRIS, REG. NO. 25,696 - NORMAN J. LATIMER, REG. NO. 19,952 - ALVIN BACLOT, REG. NO. 16,260  
IVAN P. COOPER, REG. NO. 20,005 - RONALD S. SAIDER, REG. NO. 25,852 - A. FRED STANGORIS, REG. NO. 16,453  
- SIMONE LYNNAT, REG. NO. 33,949 (Patent Agent) -

|   |   |
|---|---|
| ADDRESS ALL CORRESPONDENCE TO:<br>SHERIDAN AND NEIMARK<br>252419 Seventh Street, N.W.<br>701 Washington, D.C. 20004 | REQUEST ALL TELEPHONE CALLS TO:<br>SHERIDAN AND NEIMARK<br>(202) 628-5197 |
|---|---|

I hereby further declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code and that such willful false statements may jeopardize the validity of the application or any patent issued thereon.

|     |   |                              |         |
|-----|---|------------------------------|---------|
| 4.1 | NAME OF FIRST INVENTOR                                | SIGNATURE OF FIRST INVENTOR  | DATE    |
|     | Junming Le  | <i>Junming Le</i>            | 3/22/91 |
|     | RESIDENCE   | CITIZENSHIP                  |         |
|     | Jackson Heights, NY NY                                |                              |         |
|     | POST OFFICE ADDRESS                                   |                              |         |
|     | 33-26 92nd Street, Apt. 3X, Jackson Heights, NY 11372 |                              |         |
| 4.2 | NAME OF SECOND INVENTOR, IF ANY                       | SIGNATURE OF SECOND INVENTOR | DATE    |
|     | Jan Vilcek  | <i>Jan Vilcek</i>            | 3/22/91 |
|     | RESIDENCE   | CITIZENSHIP                  |         |
|     | New York, NY NY                                       | USA                          |         |
|     | POST OFFICE ADDRESS                                   |                              |         |
|     | 180 E. 79th Street, New York, NY 10021                |                              |         |
| 4.3 | NAME OF THIRD INVENTOR, IF ANY                        | SIGNATURE OF THIRD INVENTOR  | DATE    |
|     | Peter E. Daddona                                      | <i>Peter E. Daddona</i>      | 7/11/91 |
|     | RESIDENCE   | CITIZENSHIP                  |         |
|     | West Chester, PA PA                                   | USA                          |         |
|     | POST OFFICE ADDRESS                                   |                              |         |
|     | 642 Marydell Drive, West Chester, PA 19380            |                              |         |

11 10 00 00

|    |   |  |                |
|----|---|--|----------------|
| 44 | FULL NAME OF FOURTH JOINT INVENTOR, IF ANY<br>John Chraveb      | INVENTOR'S SIGNATURE<br><i>[Signature]</i> | DATE<br>4/1/71 |
|    | RESIDENCE<br>Thorndale, PA 17A                                  | CITIZENSHIP<br>USA                         |                |
|    | POST OFFICE ADDRESS<br>3202 Raye Road, Thorndale, PA 19372      |  |                |
| 45 | FULL NAME OF FIFTH JOINT INVENTOR, IF ANY<br>David M. Knight    | INVENTOR'S SIGNATURE<br><i>[Signature]</i> | DATE<br>4/5/71 |
|    | RESIDENCE<br>Paoli, PA 17A                                      | CITIZENSHIP<br>USA                         |                |
|    | POST OFFICE ADDRESS<br>208 Pheasant Run Drive, Paoli, PA 19301  |  |                |
| 46 | FULL NAME OF SIXTH JOINT INVENTOR, IF ANY<br>Scott A. Siegel    | INVENTOR'S SIGNATURE<br><i>[Signature]</i> | DATE<br>4/5/71 |
|    | RESIDENCE<br>West Chester, PA 17A                               | CITIZENSHIP<br>USA                         |                |
|    | POST OFFICE ADDRESS<br>1415 Hunter Lane, West Chester, PA 19380 |  |                |
|    | FULL NAME OF SEVENTH JOINT INVENTOR, IF ANY                     | INVENTOR'S SIGNATURE                       | DATE           |
|    | RESIDENCE   | CITIZENSHIP                                |                |
|    | POST OFFICE ADDRESS   |  |                |
|    | FULL NAME OF EIGHTH JOINT INVENTOR, IF ANY                      | INVENTOR'S SIGNATURE                       | DATE           |
|    | RESIDENCE   | CITIZENSHIP                                |                |
|    | POST OFFICE ADDRESS   |  |                |
|    | FULL NAME OF NINTH JOINT INVENTOR, IF ANY                       | INVENTOR'S SIGNATURE                       | DATE           |
|    | RESIDENCE   | CITIZENSHIP                                |                |
|    | POST OFFICE ADDRESS   |  |                |
|    | FULL NAME OF TENTH JOINT INVENTOR, IF ANY                       | INVENTOR'S SIGNATURE                       | DATE           |
|    | RESIDENCE   | CITIZENSHIP                                |                |
|    | POST OFFICE ADDRESS   |  |                |
|    | FULL NAME OF ELEVENTH JOINT INVENTOR, IF ANY                    | INVENTOR'S SIGNATURE                       | DATE           |
|    | RESIDENCE   | CITIZENSHIP                                |                |
|    | POST OFFICE ADDRESS   |  |                |
|    | FULL NAME OF TWELFTH JOINT INVENTOR, IF ANY                     | INVENTOR'S SIGNATURE                       | DATE           |
|    | RESIDENCE   | CITIZENSHIP                                |                |
|    | POST OFFICE ADDRESS   |  |                |
|    | FULL NAME OF THIRTEENTH JOINT INVENTOR, IF ANY                  | INVENTOR'S SIGNATURE                       | DATE           |
|    | RESIDENCE   | CITIZENSHIP                                |                |
|    | POST OFFICE ADDRESS   |  |                |
|    | FULL NAME OF FOURTEENTH JOINT INVENTOR, IF ANY                  | INVENTOR'S SIGNATURE                       | DATE           |
|    | RESIDENCE   | CITIZENSHIP                                |                |
|    | POST OFFICE ADDRESS   |  |                |

640327

-Fig-1





Fig. 2



679327

# Neutralization of TNF Cytotoxicity by Murine A2





FIG. 3



Fig 4 replace concentration = 15.10









Fig.




670327



Fig




pA2HQ1sppgt



pA2HuKsppgt

Murine A2 ELISA with chimeric A2 competitor



Chimeric A2 ELISA with murine A2 competitor




FIG. 9

# Scatchard Analysis of I-125 mA2 and cA2 IgG





Fig. 10

670827




Fig. 11



2

670827

Neutralization of ELAM-1 Expression by Chimeric A2




FIG. 12

N 19 09 09